{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:38:53Z","timestamp":1783381133246,"version":"3.54.6"},"reference-count":507,"publisher":"National Institute for Health and Care Research","issue":"26","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["15\/62\/02"],"award-info":[{"award-number":["15\/62\/02"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>There is currently no disease-modifying treatment available to halt or delay the progression of the disease pathology in dementia. An agreed core set of the best-available and most appropriate outcomes for disease modification would facilitate the design of trials and ensure consistency across disease modification trials, as well as making results comparable and meta-analysable in future trials.<\/jats:p><\/jats:sec>Objectives<\/jats:title>To agree a set of core outcomes for disease modification trials for mild to moderate dementia with the UK dementia research community and patient and public involvement (PPI).<\/jats:p><\/jats:sec>Data sources<\/jats:title>We included disease modification trials with quantitative outcomes of efficacy from (1) references from related systematic reviews in workstream 1; (2) searches of the Cochrane Dementia and Cognitive Improvement Group study register, Cochrane Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, EMBASE, Latin American and Caribbean Health Sciences Literature and PsycINFO on 11 December 2015, and clinical trial registries [International Standard Randomised Controlled Trial Number (ISRCTN) and clinicaltrials.gov] on 22 and 29 January 2016; and (3) hand-searches of reference lists of relevant systematic reviews from database searches.<\/jats:p><\/jats:sec>Review methods<\/jats:title>The project consisted of four workstreams. (1) We obtained related core outcome sets and work from co-applicants. (2) We systematically reviewed published and ongoing disease modification trials to identify the outcomes used in different domains. We extracted outcomes used in each trial, recording how many used each outcome and with how many participants. We divided outcomes into the domains measured and searched for validation data. (3) We consulted with PPI participants about recommended outcomes. (4) We presented all the synthesised information at a conference attended by the wider body of National Institute for Health Research (NIHR) dementia researchers to reach consensus on a core set of outcomes.<\/jats:p><\/jats:sec>Results<\/jats:title>We included 149 papers from the 22,918 papers screened, referring to 125 individual trials. Eighty-one outcomes were used across trials, including 72 scales [31 cognitive, 12 activities of daily living (ADLs), 10 global, 16 neuropsychiatric and three quality of life] and nine biological techniques. We consulted with 18 people for PPI. The conference decided that only cognition and biological markers are core measures of disease modification. Cognition should be measured by the Mini Mental State Examination (MMSE) or the Alzheimer\u2019s Disease Assessment Scale \u2013 Cognitive subscale (ADAS-Cog), and brain changes through structural magnetic resonance imaging (MRI) in a subset of participants. All other domains are important but not core. We recommend using the Neuropsychiatric Inventory for neuropsychiatric symptoms: the Disability Assessment for Dementia for ADLs, the Dementia Quality of Life Measure for quality of life and the Clinical Dementia Rating scale to measure dementia globally.<\/jats:p><\/jats:sec>Limitations<\/jats:title>Most of the trials included participants with Alzheimer\u2019s disease, so recommendations may not apply to other types of dementia. We did not conduct economic analyses. The PPI consultation was limited to members of the Alzheimer\u2019s Society Research Network.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Cognitive outcomes and biological markers form the core outcome set for future disease modification trials, measured by the MMSE or ADAS-Cog, and structural MRI in a subset of participants.<\/jats:p><\/jats:sec>Future work<\/jats:title>We envisage that the core set may be superseded in the future, particularly for other types of dementia. There is a need to develop an algorithm to compare scores on the MMSE and ADAS-Cog.<\/jats:p><\/jats:sec>Study registration<\/jats:title>The project was registered with Core Outcome Measures in Effectiveness Trials [www.comet-initiative.org\/studies\/details\/819?result=true<\/jats:uri>(accessed 7 April 2016)]. The systematic review protocol is registered as PROSPERO CRD42015027346.<\/jats:p><\/jats:sec>Funding<\/jats:title>The National Institute for Health Research Health Technology Assessment programme.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta21260","type":"journal-article","created":{"date-parts":[[2017,6,19]],"date-time":"2017-06-19T07:48:41Z","timestamp":1497858521000},"page":"1-192","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations"],"prefix":"10.3310","volume":"21","author":[{"given":"Lucy","family":"Webster","sequence":"first","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Groskreutz","sequence":"additional","affiliation":[{"name":"Division of Psychology and Language Sciences, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grinbergs-Saull","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Society, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Howard","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Mountain","sequence":"additional","affiliation":[{"name":"School of Health and Related Research, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sube","family":"Banerjee","sequence":"additional","affiliation":[{"name":"Brighton and Sussex Medical School, University of Sussex, Brighton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"Woods","sequence":"additional","affiliation":[{"name":"Dementia Services Development Centre Wales, Bangor University, Bangor, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Perneczky","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, School of Public Health, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Lafortune","sequence":"additional","affiliation":[{"name":"Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Roberts","sequence":"additional","affiliation":[{"name":"International Consortium for Health Outcomes Measurement, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"McCleery","sequence":"additional","affiliation":[{"name":"Oxford Health NHS Foundation Trust, Banbury, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Pickett","sequence":"additional","affiliation":[{"name":"Alzheimer\u2019s Society, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"Bunn","sequence":"additional","affiliation":[{"name":"Centre for Research in Primary and Community Care, University of Hertfordshire, Hatfield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Challis","sequence":"additional","affiliation":[{"name":"Personal Social Services Research Unit, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Charlesworth","sequence":"additional","affiliation":[{"name":"Research Department of Clinical, Educational, and Health Psychology, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Featherstone","sequence":"additional","affiliation":[{"name":"School of Healthcare Sciences, Cardiff University, Cardiff, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Fox","sequence":"additional","affiliation":[{"name":"Norwich Medical School, University of East Anglia, Norwich, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Goodman","sequence":"additional","affiliation":[{"name":"Centre for Research in Primary and Community Care, University of Hertfordshire, Hatfield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Jones","sequence":"additional","affiliation":[{"name":"Research Institute for the Care of Older People, University of Bath, Bath, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sallie","family":"Lamb","sequence":"additional","affiliation":[{"name":"Oxford Clinical Trials Research Unit, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esme","family":"Moniz-Cook","sequence":"additional","affiliation":[{"name":"Faculty of Health and Social Care, University of Hull, Hull, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Schneider","sequence":"additional","affiliation":[{"name":"Institute of Mental Health, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasha","family":"Shepperd","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Surr","sequence":"additional","affiliation":[{"name":"School of Health & Community Studies, Leeds Beckett University, Leeds, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Thompson-Coon","sequence":"additional","affiliation":[{"name":"Collaboration for Leadership in Applied Health Research and Care South West Peninsula, University of Exeter, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[{"name":"Wolfson Centre for Age-Related Diseases, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Brayne","sequence":"additional","affiliation":[{"name":"Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlaith","family":"Burke","sequence":"additional","affiliation":[{"name":"Nuffield Department of Population Health, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair","family":"Burns","sequence":"additional","affiliation":[{"name":"Institute of Brain, Behaviour and Mental Health, University of Manchester, Manchester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Clare","sequence":"additional","affiliation":[{"name":"Collaboration for Leadership in Applied Health Research and Care South West Peninsula, University of Exeter, Exeter, UK"},{"name":"School of Psychology, University of Exeter, Exeter, UK"},{"name":"Centre for Research in Ageing and Cognitive Health, University of Exeter Medical School, Exeter, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Garrard","sequence":"additional","affiliation":[{"name":"Neuroscience Research Centre, St George\u2019s, University of London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kehoe","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences, University of Bristol, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Passmore","sequence":"additional","affiliation":[{"name":"Centre for Public Health, Queen\u2019s University Belfast, Belfast, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Holmes","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Southampton, Southampton, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Maidment","sequence":"additional","affiliation":[{"name":"Aston Research Centre for Healthy Ageing, Aston University, Birmingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fliss","family":"Murtagh","sequence":"additional","affiliation":[{"name":"Cicely Saunders Institute, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Robinson","sequence":"additional","affiliation":[{"name":"Institute of Health and Society, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gill","family":"Livingston","sequence":"additional","affiliation":[{"name":"Division of Psychiatry, University College London, London, UK"},{"name":"Camden and Islington NHS Foundation Trust, London, UK"},{"name":"North Thames Collaboration for Leadership in Applied Health Research and Care, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2017,5]]},"reference":[{"key":"key20170509113253506_ref1-bib1","volume-title":"Dementia UK: Update","author":"Prince","year":"2014"},{"key":"key20170509113253506_ref1-bib2","volume-title":"Estimation of Future Cases of Dementia from those Born in 2015","author":"Lewis","year":"2015"},{"key":"key20170509113253506_ref1-bib3","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(13)61570-6","article-title":"A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II","volume":"382","author":"Matthews","year":"2013","journal-title":"Lancet"},{"key":"key20170509113253506_ref1-bib4","doi-asserted-by":"publisher","first-page":"11398","DOI":"10.1038\/ncomms11398","article-title":"A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II","volume":"7","author":"Matthews","year":"2016","journal-title":"Nat Commun"},{"key":"key20170509113253506_ref1-bib5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","article-title":"Potential for primary prevention of Alzheimer\u2019s disease: an analysis of population-based data","volume":"13","author":"Norton","year":"2014","journal-title":"Lancet Neurol"},{"key":"key20170509113253506_ref1-bib6","volume-title":"First WHO Ministerial Conference on Global Action Against Dementia: Meeting Report, WHO Headquarters, Geneva, Switzerland, 16\u201317 March 2015","author":"World Health Organization","year":"2015"},{"key":"key20170509113253506_ref1-bib7","doi-asserted-by":"publisher","first-page":"e004119","DOI":"10.1136\/bmjopen-2013-004119","article-title":"Diagnostic rates and treatment of dementia before and after launch of a national dementia policy: an observational study using English national databases","volume":"4","author":"Mukadam","year":"2014","journal-title":"BMJ Open"},{"key":"key20170509113253506_ref1-bib8","volume-title":"World Alzheimer Report 2011: The Benefits of Early Diagnosis and Intervention","author":"Prince","year":"2011"},{"key":"key20170509113253506_ref1-bib9","volume-title":"ISRCTN93682878 Reducing Pathology in Alzheimer\u2019s Disease Through Angiotensin Targeting","author":"NIHR","year":"2015"},{"key":"key20170509113253506_ref1-bib10","volume-title":"ISRCTN16105064 Minocycline in Alzheimer\u2019s Disease","author":"Medical Research Council\/NIHR Efficacy and Mechanism Evaluation Programme","year":"2013"},{"key":"key20170509113253506_ref1-bib11","volume-title":"Researching Alzheimer\u2019s Medicines: Setbacks and Stepping Stones","author":"Pharmaceutical Research and Manufacturers of America","year":"2012"},{"key":"key20170509113253506_ref1-bib12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1002\/gps.1166","article-title":"The place of memantine in the treatment of Alzheimer\u2019s disease: a number needed to treat analysis","volume":"19","author":"Livingston","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib13","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2147\/DDDT.S41431","article-title":"Disease-modifying drugs in Alzheimer\u2019s disease","volume":"7","author":"Ghezzi","year":"2013","journal-title":"Drug Des Devel Ther"},{"key":"key20170509113253506_ref1-bib14","volume-title":"The Trajectory of Dementia in the UK \u2013 Making a Difference","author":"Lewis","year":"2014"},{"key":"key20170509113253506_ref1-bib15","volume-title":"G8 Dementia Summit Declaration","author":"Global Action against Dementia","year":"2013"},{"key":"key20170509113253506_ref1-bib16","first-page":"44","article-title":"New standards in Alzheimer\u2019s disease trial design","volume":"6","author":"Zoda","year":"2014","journal-title":"Therapeutics J Clin Studies"},{"key":"key20170509113253506_ref1-bib17","volume-title":"A Call to Action: The Global Response to Dementia Through Policy Innovation","author":"Rubinstein","year":"2015"},{"key":"key20170509113253506_ref1-bib18","volume-title":"Challenges to Finding Treatments for Dementia","author":"Long","year":"2015"},{"key":"key20170509113253506_ref1-bib19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jalz.2015.12.003","article-title":"Why has therapy development for dementia failed in the last two decades?","volume":"12","author":"Gauthier","year":"2016","journal-title":"Alzheimers Dement"},{"key":"key20170509113253506_ref1-bib20","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMp1511701","article-title":"Standardizing patient outcomes measurement","volume":"374","author":"Porter","year":"2016","journal-title":"N Engl J Med"},{"key":"key20170509113253506_ref1-bib21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/gps.3958","article-title":"Patient and carer views on participating in clinical trials for prodromal Alzheimer\u2019s disease and mild cognitive impairment","volume":"29","author":"Lawrence","year":"2014","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib22","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"key20170509113253506_ref1-bib23","volume-title":"\u2018What Works\u2019 in Dementia Education and Training?","author":"Leeds Beckett University"},{"key":"key20170509113253506_ref1-bib24","volume-title":"NCT01409915 Study of the Safety & Efficacy of Leukine\u00ae in the Treatment of Alzheimer\u2019s Disease","author":"University of Colorado Denver","year":"2016"},{"key":"key20170509113253506_ref1-bib25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1034\/j.1600-0404.2000.00312.x","article-title":"Anti-inflammatory therapy for Alzheimer\u2019s disease: implications of the prednisone trial","volume":"176","author":"Aisen","year":"2000","journal-title":"Acta Neurol Scand Suppl"},{"key":"key20170509113253506_ref1-bib26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1212\/WNL.54.3.588","article-title":"A randomized controlled trial of prednisone in Alzheimer\u2019s disease. Alzheimer\u2019s Disease Cooperative Study","volume":"54","author":"Aisen","year":"2000","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib27","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1212\/WNL.58.7.1050","article-title":"Randomized pilot study of nimesulide treatment in Alzheimer\u2019s disease","volume":"58","author":"Aisen","year":"2002","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib28","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","article-title":"Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial","volume":"289","author":"Aisen","year":"2003","journal-title":"JAMA"},{"key":"key20170509113253506_ref1-bib29","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1212\/01.wnl.0000244346.08950.64","article-title":"A Phase II study targeting amyloid-beta with 3APS in mild to moderate Alzheimer disease","volume":"67","author":"Aisen","year":"2006","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib30","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1994","edition":"4th edn."},{"key":"key20170509113253506_ref1-bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2174\/156720507781788882","article-title":"Alzhemed: a potential treatment for Alzheimer\u2019s disease","volume":"4","author":"Aisen","year":"2007","journal-title":"Curr Alzheimer Res"},{"key":"key20170509113253506_ref1-bib32","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jama.300.15.1774","article-title":"High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial","volume":"300","author":"Aisen","year":"2008","journal-title":"JAMA"},{"key":"key20170509113253506_ref1-bib33","first-page":"3","article-title":"High-dose vitamin B does not slow cognitive decline in AD","volume":"12","author":"National Institute of Aging, the General Clinical Research Center Programme","year":"2008","journal-title":"Brown Uni Geriatr Psychopharmacol Update"},{"key":"key20170509113253506_ref1-bib34","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/archneurol.2009.12","article-title":"High-dose B vitamin supplementation as a disease-modifying therapy in Alzheimer disease","volume":"66","author":"Viswanathan","year":"2009","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild to moderate Alzheimer\u2019s disease \u2013 a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch Med Sci"},{"key":"key20170509113253506_ref1-bib36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s12603-009-0106-x","article-title":"Effect of tramiprosate in patients with mild to moderate Alzheimer\u2019s disease: exploratory analyses of the MRI sub-group of the Alphase study","volume":"13","author":"Gauthier","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"key20170509113253506_ref1-bib37","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s12603-009-0217-4","article-title":"Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer\u2019s disease: ADAS-cog subscale results from the Alphase Study","volume":"13","author":"Saumier","year":"2009","journal-title":"J Nutr Health Aging"},{"key":"key20170509113253506_ref1-bib38","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00213-009-1706-1","article-title":"A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild to moderate Alzheimer\u2019s disease","volume":"207","author":"Akhondzadeh","year":"2010","journal-title":"Psychopharmacology"},{"key":"key20170509113253506_ref1-bib39","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/j.1365-2710.2009.01133.x","article-title":"Saffron in the treatment of patients with mild to moderate Alzheimer\u2019s disease: a 16-week, randomized and placebo-controlled trial","volume":"35","author":"Akhondzadeh","year":"2010","journal-title":"J Clin Pharm Ther"},{"key":"key20170509113253506_ref1-bib40","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1358\/mf.2000.22.7.802270","article-title":"Double-blind, randomized, placebo-controlled pilot study with Anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics","volume":"22","author":"Alvarez","year":"2000","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"key20170509113253506_ref1-bib41","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1468-1331.2006.01222.x","article-title":"A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer\u2019s disease","volume":"13","author":"Alvarez","year":"2006","journal-title":"Eur J Neurol"},{"key":"key20170509113253506_ref1-bib42","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1468-1331.2010.03092.x","article-title":"Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer\u2019s disease: results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin","volume":"18","author":"Alvarez","year":"2011","journal-title":"Eur J Neurol"},{"key":"key20170509113253506_ref1-bib43","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0306-4530(99)00020-7","article-title":"Cognitive and neuroendocrine response to transdermal estrogen in postmenopausal women with Alzheimer\u2019s disease: results of a placebo-controlled, double-blind, pilot study","volume":"24","author":"Asthana","year":"1999","journal-title":"Psychoneuroendocrinology"},{"key":"key20170509113253506_ref1-bib44","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.clinph.2009.02.005","article-title":"Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer\u2019s disease","volume":"120","author":"Babiloni","year":"2009","journal-title":"Clin Neurophysiol"},{"key":"key20170509113253506_ref1-bib45","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF03325217","article-title":"A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer\u2019s disease","volume":"21","author":"Pasqualetti","year":"2009","journal-title":"Aging Clin Exp Res"},{"key":"key20170509113253506_ref1-bib46","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/j.1532-5415.2000.tb03865.x","article-title":"A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer\u2019s disease","volume":"48","author":"Bae","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib47","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0278-5846(90)90005-2","article-title":"Nimodipine in the treatment of old age dementias","volume":"14","author":"Ban","year":"1990","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key20170509113253506_ref1-bib48","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"1987","edition":"3rd edn."},{"key":"key20170509113253506_ref1-bib49","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","article-title":"Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD","volume":"64","author":"Bayer","year":"2005","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib50","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of Abeta42 immunisation in Alzheimer\u2019s disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"key20170509113253506_ref1-bib51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1474-4422(07)70293-4","article-title":"Aspirin in Alzheimer\u2019s disease (AD2000): a randomised open-label trial","volume":"7","author":"Bentham","year":"2008","journal-title":"Lancet Neurol"},{"key":"key20170509113253506_ref1-bib52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3233\/JAD-2004-6103","article-title":"Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer\u2019s disease","volume":"6","author":"Bilikiewicz","year":"2004","journal-title":"J Alzheimers Dis"},{"key":"key20170509113253506_ref1-bib53","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/WAD.0b013e3181c53b00","article-title":"A single ascending dose study of bapineuzumab in patients with Alzheimer disease","volume":"24","author":"Black","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib54","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1001\/archneurol.2012.90","article-title":"Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease","volume":"69","author":"Blennow","year":"2012","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib55","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1474-4422(10)70043-0","article-title":"11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer\u2019s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study","volume":"9","author":"Rinne","year":"2010","journal-title":"Lancet Neurol"},{"key":"key20170509113253506_ref1-bib56","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib57","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3233\/JAD-141626","article-title":"A clinical study of Lupron depot in the treatment of women with Alzheimer\u2019s disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose Lupron over 48 weeks","volume":"44","author":"Bowen","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"key20170509113253506_ref1-bib58","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3233\/JAD-141791","article-title":"Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer\u2019s disease dementia","volume":"44","author":"Claxton","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"key20170509113253506_ref1-bib59","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib60","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/0140-6736(91)92978-B","article-title":"Intramuscular desferrioxamine in patients with Alzheimer\u2019s disease","volume":"337","author":"Crapper McLachlan","year":"1991","journal-title":"Lancet"},{"key":"key20170509113253506_ref1-bib61","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/00007691-199312000-00027","article-title":"Desferrioxamine and Alzheimer\u2019s disease: video home behavior assessment of clinical course and measures of brain aluminium","volume":"15","author":"McLachlan","year":"1993","journal-title":"Ther Drug Monit"},{"key":"key20170509113253506_ref1-bib62","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0167-4943(98)80018-6","article-title":"Dihydroergocryptine as long-term treatment of Alzheimer type dementia: a multicenter two-year follow-up","volume":"27","author":"Cucinotta","year":"1998","journal-title":"Arch Gerontol Geriatr"},{"key":"key20170509113253506_ref1-bib63","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1474-4422(13)70014-0","article-title":"Intravenous immunoglobulin for treatment of mild to moderate Alzheimer\u2019s disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial","volume":"12","author":"Dodel","year":"2013","journal-title":"Lancet Neurol"},{"key":"key20170509113253506_ref1-bib64","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","article-title":"Effect of Dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild to moderate Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled study","volume":"372","author":"Doody","year":"2008","journal-title":"Lancet"},{"key":"key20170509113253506_ref1-bib65","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer\u2019s disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"key":"key20170509113253506_ref1-bib66","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-015-0121-6","article-title":"Peripheral and central effects of \u03b3-secretase inhibition by semagacestat in Alzheimer\u2019s disease","volume":"7","author":"Doody","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"key20170509113253506_ref1-bib67","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild to moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"key":"key20170509113253506_ref1-bib68","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.trci.2015.06.006","article-title":"Delayed-start analysis: mild Alzheimer\u2019s disease patients in solanezumab trials, 3.5 years","volume":"1","author":"Liu-Seifert","year":"2015","journal-title":"Alzheimers Dement Translat Res Clin Intervent"},{"key":"key20170509113253506_ref1-bib69","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1212\/WNL.0000000000001017","article-title":"Increased CSF APPs-\u03b1 levels in patients with Alzheimer disease treated with acitretin","volume":"83","author":"Endres","year":"2014","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib70","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.jalz.2011.09.224","article-title":"Safety and biomarker effects of solanezumab in patients with Alzheimer\u2019s disease","volume":"8","author":"Farlow","year":"2012","journal-title":"Alzheimers Dement"},{"key":"key20170509113253506_ref1-bib71","doi-asserted-by":"publisher","first-page":"509","DOI":"10.3233\/JAD-2010-1390","article-title":"PBT2 rapidly improves cognition in Alzheimer\u2019s Disease: additional phase II analyses","volume":"20","author":"Faux","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"key20170509113253506_ref1-bib72","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1474-4422(08)70167-4","article-title":"Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer\u2019s disease: a phase IIa, double-blind, randomised, placebo-controlled trial","volume":"7","author":"Lannfelt","year":"2008","journal-title":"Lancet Neurol"},{"key":"key20170509113253506_ref1-bib73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JAD-121828","article-title":"Effects on transthyretin in plasma and cerebrospinal fluid by DHA-rich n-3 fatty acid supplementation in patients with Alzheimer\u2019s disease: the OmegAD study","volume":"36","author":"Fax\u00e9n-Irving","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"key20170509113253506_ref1-bib74","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1001\/archneur.63.10.1402","article-title":"Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial","volume":"63","author":"Freund-Levi","year":"2006","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib75","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0167-4943(98)80024-1","article-title":"Effectiveness and safety of posatirelin in the treatment of senile dementia: a multicenter, double-blind, placebo-controlled study","volume":"6","author":"Ferrari","year":"1998","journal-title":"Arch Gerontol Geriatr"},{"key":"key20170509113253506_ref1-bib76","volume-title":"The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization","year":"1992"},{"key":"key20170509113253506_ref1-bib77","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archneur.65.8.1031","article-title":"Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease","volume":"65","author":"Fleisher","year":"2008","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib78","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1212\/WNL.0b013e318230a16c","article-title":"Chronic divalproex sodium use and brain atrophy in Alzheimer disease","volume":"77","author":"Fleisher","year":"2011","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib79","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fox","year":"2005","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib80","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib81","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0896-6273(03)00294-0","article-title":"Antibodies against beta-amyloid slow cognitive decline in Alzheimer\u2019s disease","volume":"38","author":"Hock","year":"2003","journal-title":"Neuron"},{"key":"key20170509113253506_ref1-bib82","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1212\/01.wnl.0000278226.96003.f8","article-title":"An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer disease","volume":"69","author":"Koepsell","year":"2007","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib83","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/01.WNL.0000073623.84147.A8","article-title":"Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization","volume":"61","author":"Orgogozo","year":"2003","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib84","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/156720509787602852","article-title":"Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders","volume":"6","author":"Vellas","year":"2009","journal-title":"Curr Alzheimer Res"},{"key":"key20170509113253506_ref1-bib85","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/archneurol.2012.85","article-title":"Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures","volume":"69","author":"Galasko","year":"2012","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib86","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1212\/WNL.0000000000000364","article-title":"Clinical trial of an inhibitor of RAGE-A\u03b2 interactions in Alzheimer disease","volume":"82","author":"Galasko","year":"2014","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib87","doi-asserted-by":"publisher","first-page":"473","DOI":"10.3233\/JAD-150414","article-title":"Effects of the acetylcholine release agent ST101 with donepezil in Alzheimer\u2019s disease: a randomized phase 2 study","volume":"48","author":"Gauthier","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"key20170509113253506_ref1-bib88","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/archneurol.2010.229","article-title":"A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease","volume":"68","author":"Geldmacher","year":"2011","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib89","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild to moderate Alzheimer\u2019s disease: results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib90","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1001\/jama.2009.1866","article-title":"Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial","volume":"302","author":"Green","year":"2009","journal-title":"JAMA"},{"key":"key20170509113253506_ref1-bib91","first-page":"1","article-title":"No significant effect of tarenflurbil on cognition in early Alzheimer\u2019s disease","volume":"14","author":"Myrexis, Inc","year":"2010","journal-title":"Brown Uni Geriatr Psychopharmacol Update"},{"key":"key20170509113253506_ref1-bib92","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1742-2094-11-30","article-title":"A pilot study on the use of interferon beta-1a in early Alzheimer\u2019s disease subjects","volume":"11","author":"Grimaldi","year":"2014","journal-title":"J Neuroinflammation"},{"key":"key20170509113253506_ref1-bib93","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in Alzheimer\u2019s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"key20170509113253506_ref1-bib94","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/13506120308995249","article-title":"Treatment with the selective muscarinic m1 agonist talsaclidine decreases cerebrospinal fluid levels of A beta 42 in patients with Alzheimer\u2019s disease","volume":"10","author":"Hock","year":"2003","journal-title":"Amyloid"},{"key":"key20170509113253506_ref1-bib95","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/j.1749-6632.2000.tb06937.x","article-title":"Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of total amyloid beta-peptide in patients with Alzheimer\u2019s disease","volume":"920","author":"Hock","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"key20170509113253506_ref1-bib96","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1081\/CRP-120030034","article-title":"A pharmacokinetic, pharmacodynamic, and safety study of celecoxib in subjects with probable Alzheimer\u2019s disease","volume":"21","author":"Jhee","year":"2004","journal-title":"Clin Res Regul Aff"},{"key":"key20170509113253506_ref1-bib97","doi-asserted-by":"publisher","first-page":"e1475","DOI":"10.1371\/journal.pone.0001475","article-title":"No effect of one-year treatment with indomethacin on Alzheimer\u2019s disease progression: a randomized controlled trial","volume":"3","author":"de Jong","year":"2008","journal-title":"PLOS ONE"},{"key":"key20170509113253506_ref1-bib98","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ana.21345","article-title":"Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer\u2019s disease","volume":"63","author":"Kadir","year":"2008","journal-title":"Ann Neurol"},{"key":"key20170509113253506_ref1-bib99","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00702-008-0136-2","article-title":"Effect of copper intake on CSF parameters in patients with mild Alzheimer\u2019s disease: a pilot phase 2 clinical trial","volume":"115","author":"Kessler","year":"2008","journal-title":"J Neural Transm"},{"key":"key20170509113253506_ref1-bib100","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00702-008-0080-1","article-title":"Intake of copper has no effect on cognition in patients with mild Alzheimer\u2019s disease: a pilot phase 2 clinical trial","volume":"115","author":"Kessler","year":"2008","journal-title":"J Neural Transm"},{"key":"key20170509113253506_ref1-bib101","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/WNF.0b013e31827db49b","article-title":"Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild to moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study","volume":"36","author":"Landen","year":"2013","journal-title":"Clin Neuropharmacol"},{"key":"key20170509113253506_ref1-bib102","first-page":"377","article-title":"Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer\u2019s disease. A double-blind, placebo-controlled study","volume":"47","author":"Leszek","year":"1999","journal-title":"Arch Immunol Ther Exp"},{"key":"key20170509113253506_ref1-bib103","doi-asserted-by":"publisher","first-page":"103985","DOI":"10.1155\/2015\/103985","article-title":"Neuroprotective Effects of cistanches herba therapy on patients with moderate Alzheimer\u2019s Disease","volume":"2015","author":"Li","year":"2015","journal-title":"Evid Based Complement Alternat Med"},{"key":"key20170509113253506_ref1-bib104","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer\u2019s disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"key20170509113253506_ref1-bib105","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.trci.2015.06.003","article-title":"A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer\u2019s disease","volume":"1","author":"Maher-Edwards","year":"2015","journal-title":"Alzheimers Dement Translat Res Clin Intervent"},{"key":"key20170509113253506_ref1-bib106","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000106650","article-title":"A 12-month, randomized, placebo-controlled trial of propentofylline (HWA 285) in patients with dementia according to DSM III-R. The European Propentofylline Study Group","volume":"8","author":"Marcusson","year":"1997","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib107","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/gps.3846","article-title":"A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer\u2019s disease: the DARAD trial","volume":"28","author":"Molloy","year":"2013","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib108","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-3-7091-6139-5_25","article-title":"Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin","volume":"62","author":"Muresanu","year":"2002","journal-title":"J Neural Transm Suppl"},{"key":"key20170509113253506_ref1-bib109","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jns.2007.10.016","article-title":"A pilot study to evaluate the effects of Cerebrolysin on cognition and qEEG in vascular dementia: cognitive improvement correlates with qEEG acceleration","volume":"267","author":"Muresanu","year":"2008","journal-title":"J Neurol Sci"},{"key":"key20170509113253506_ref1-bib110","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13195-015-0119-0","article-title":"A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer\u2019s disease","volume":"7","author":"Nygaard","year":"2015","journal-title":"Alzheimers Res Ther"},{"key":"key20170509113253506_ref1-bib111","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib112","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"key":"key20170509113253506_ref1-bib113","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000051288","article-title":"Treatment of Alzheimer\u2019s disease with clioquinol","volume":"12","author":"Regland","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib114","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.62.1.66","article-title":"Rofecoxib: no effect on Alzheimer\u2019s disease in a 1-year, randomized, blinded, controlled study","volume":"62","author":"Reines","year":"2004","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib115","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/alzrt146","article-title":"Oral curcumin for Alzheimer\u2019s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study","volume":"4","author":"Ringman","year":"2012","journal-title":"Alzheimers Res Ther"},{"key":"key20170509113253506_ref1-bib116","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1001\/archneur.60.12.1685","article-title":"Metal\u2013protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial","volume":"60","author":"Ritchie","year":"2003","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib117","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s007020070061","article-title":"Sustained improvements in patients with dementia of Alzheimer\u2019s type (DAT) 6 months after termination of Cerebrolysin therapy","volume":"107","author":"R\u00fcther","year":"2000","journal-title":"J Neural Transm"},{"key":"key20170509113253506_ref1-bib118","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1055\/s-2007-1014271","article-title":"Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT)","volume":"27","author":"R\u00fcther","year":"1994","journal-title":"Pharmacopsychiatry"},{"key":"key20170509113253506_ref1-bib119","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00004850-200109000-00002","article-title":"A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer\u2019s disease","volume":"16","author":"Ruether","year":"2001","journal-title":"Int Clin Psychopharmacol"},{"key":"key20170509113253506_ref1-bib120","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/978-3-7091-6139-5_24","article-title":"Sustained improvement of cognition and global function in patients with moderately severe Alzheimer\u2019s disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin","volume":"62","author":"Ruether","year":"2002","journal-title":"J Neural Transm Suppl"},{"key":"key20170509113253506_ref1-bib121","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib122","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild to moderate Alzheimer\u2019s disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N Engl J Med"},{"key":"key20170509113253506_ref1-bib123","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00002093-199601030-00004","article-title":"Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer\u2019s Disease Cooperative Study","volume":"10","author":"Sano","year":"1996","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib124","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1212\/WNL.0b013e318228bf11","article-title":"A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease","volume":"77","author":"Sano","year":"2011","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1212\/WNL.53.1.197","article-title":"A double-blind, placebo-controlled trial of diclofenac\/misoprostol in Alzheimer\u2019s disease","volume":"53","author":"Scharf","year":"1999","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib126","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/1567205011666140505100858","article-title":"A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer\u2019s disease","volume":"11","author":"Schwam","year":"2014","journal-title":"Curr Alzheimer Res"},{"key":"key20170509113253506_ref1-bib127","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer\u2019s disease with the GSK-3 inhibitor tideglusib: a pilot study","volume":"33","author":"del Ser","year":"2013","journal-title":"J Alzheimers Dis"},{"key":"key20170509113253506_ref1-bib128","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1212\/01.wnl.0000335163.88054.e7","article-title":"Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial","volume":"71","author":"Sevigny","year":"2008","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib129","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/WNF.0b013e3181cb577a","article-title":"Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease","volume":"33","author":"Siemers","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"key20170509113253506_ref1-bib130","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1212\/01.WNL.0000031794.42077.A1","article-title":"Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study","volume":"59","author":"Silverberg","year":"2002","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib131","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1212\/01.wnl.0000316197.04157.6f","article-title":"Continuous CSF drainage in AD: results of a double-blind, randomized, placebo-controlled study","volume":"71","author":"Silverberg","year":"2008","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib132","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1002\/ana.10292","article-title":"Treatment with simvastatin in normocholesterolemic patients with Alzheimer\u2019s disease: a 26-week randomized, placebo-controlled, double-blind trial","volume":"52","author":"Simons","year":"2002","journal-title":"Ann Neurol"},{"key":"key20170509113253506_ref1-bib133","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000096588","article-title":"Long-term efficacy and safety of celecoxib in Alzheimer\u2019s disease","volume":"23","author":"Soininen","year":"2007","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib134","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archneur.62.5.753","article-title":"Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results","volume":"62","author":"Sparks","year":"2005","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib135","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/11631260-000000000-00000","article-title":"Phase III CONCERT trial of latrepirdine: negative results","volume":"26","author":"Sweetlove","year":"2012","journal-title":"Pharmaceut Med"},{"key":"key20170509113253506_ref1-bib136","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/tam.6.1.13.17","article-title":"A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer\u2019s disease","volume":"6","author":"Tan","year":"2003","journal-title":"Aging Male"},{"key":"key20170509113253506_ref1-bib137","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease","volume":"85","author":"Turner","year":"2015","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib138","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0140-6736(01)05623-9","article-title":"Effect of hydroxychloroquine on progression of dementia in early Alzheimer\u2019s disease: an 18-month randomised, double-blind, placebo-controlled study","volume":"358","author":"Van Gool","year":"2001","journal-title":"Lancet"},{"key":"key20170509113253506_ref1-bib139","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2174\/156720511795256053","article-title":"EHT0202 in Alzheimer\u2019s disease: a 3-month, randomized, placebo-controlled, double-blind study","volume":"8","author":"Vellas","year":"2011","journal-title":"Curr Alzheimer Res"},{"key":"key20170509113253506_ref1-bib140","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/JCP.0b013e31829a876a","article-title":"Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial","volume":"33","author":"Wang","year":"2013","journal-title":"J Clin Psychopharmacol"},{"key":"key20170509113253506_ref1-bib141","first-page":"950","article-title":"Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study","volume":"13","author":"Watson","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib142","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/S1474-4422(08)70090-5","article-title":"Efficacy and safety of tarenflurbil in mild to moderate Alzheimer\u2019s disease: a randomised phase II trial","volume":"7","author":"Wilcock","year":"2008","journal-title":"Lancet Neurol"},{"key":"key20170509113253506_ref1-bib143","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2165\/00044011-200121090-00004","article-title":"Nicergoline in the treatment of mild to moderate Alzheimer\u2019s disease: a European multicentre trial","volume":"21","author":"Winblad","year":"2001","journal-title":"Clin Drug Invest"},{"key":"key20170509113253506_ref1-bib144","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer\u2019s disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol"},{"key":"key20170509113253506_ref1-bib145","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3233\/JAD-142874","article-title":"Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer\u2019s disease","volume":"44","author":"Wischik","year":"2015","journal-title":"J Alzheimers Dis"},{"key":"key20170509113253506_ref1-bib146","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1212\/01.WNL.0000052994.54660.58","article-title":"DHEA treatment of Alzheimer\u2019s disease: a randomized, double-blind, placebo-controlled study","volume":"60","author":"Wolkowitz","year":"2003","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib147","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/1745-6215-12-230","article-title":"Alzheimer\u2019s disease \u2013 input of vitamin D with mEmantine assay (AD-IDEA trial): study protocol for a randomized controlled trial","volume":"12","author":"Annweiler","year":"2011","journal-title":"Trials"},{"key":"key20170509113253506_ref1-bib148","first-page":"A4519","article-title":"Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer\u2019s disease \u2013 protocol for a controlled, randomized double-blinded trial","volume":"59","author":"Egefjord","year":"2012","journal-title":"Dan Med J"},{"key":"key20170509113253506_ref1-bib149","doi-asserted-by":"crossref","first-page":"e006364","DOI":"10.1136\/bmjopen-2014-006364","article-title":"NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild to moderate Alzheimer\u2019s disease","volume":"4","author":"Lawlor","year":"2014","journal-title":"BMJ Open"},{"key":"key20170509113253506_ref1-bib150","volume-title":"ISRCTN31208535 A Clinical Trial To Test Amlodipine as a New Treatment for Vascular Dementia","author":"Alzheimer\u2019s Society","year":"2016"},{"key":"key20170509113253506_ref1-bib151","volume-title":"ISRCTN89711766 Evaluating the Effects of the Novel GLP1 Analogue, Liraglutide, in Patients with Alzheimer\u2019s Disease (ELAD study)","author":"Alzheimer\u2019s Society","year":"2015"},{"key":"key20170509113253506_ref1-bib152","volume-title":"NCT01561053 A Study to Evaluate Albumin and Immunoglobulin in Alzheimer\u2019s Disease (AMBAR)","author":"Instituto Grifols SA","year":"2015"},{"key":"key20170509113253506_ref1-bib153","volume-title":"NCT01767311 A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer\u2019s Disease","author":"Eisai Inc","year":"2016"},{"key":"key20170509113253506_ref1-bib154","volume-title":"NCT01965756 Effect of Insulin Sensitizer Metformin on AD Biomarkers","author":"University of Pennsylvania","year":"2013"},{"key":"key20170509113253506_ref1-bib155","volume-title":"NCT01966666 A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer\u2019s Disease","author":"University of California, San Francisco","year":"2016"},{"key":"key20170509113253506_ref1-bib156","volume-title":"NCT02036645 SAD\/MAD Study to Assess Safety, Tolerability, PK & PD of MEDI1814 in Subjects With Mild-Moderate Alzheimer\u2019s Disease","author":"AstraZeneca","year":"2016"},{"key":"key20170509113253506_ref1-bib157","volume-title":"NCT02051608 A Study of Gantenerumab in Patients With Mild Alzheimer Disease","author":"Hoffmann-La Roche","year":"2016"},{"key":"key20170509113253506_ref1-bib158","volume-title":"NCT02080364 Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer\u2019s Disease (STEADFAST)","author":"vTv Therapeutics","year":"2016"},{"key":"key20170509113253506_ref1-bib159","volume-title":"NCT02245737 An Efficacy and Safety Study of LY3314814 in Early Alzheimer\u2019s Disease (AMARANTH)","author":"Eli Lilly and Company","year":"2016"},{"key":"key20170509113253506_ref1-bib160","volume-title":"NCT02322021 Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer\u2019s Disease (Prodromal Alzheimer\u2019s Disease) and Mild to Moderate Dementia Due to Alzheimer\u2019s Disease","author":"Eisai Inc., Biogen","year":"2015"},{"key":"key20170509113253506_ref1-bib161","volume-title":"NCT02353598 A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease","author":"Genentech Inc","year":"2016"},{"key":"key20170509113253506_ref1-bib162","volume-title":"NCT02386306 Study Evaluating Safety, Tolerability, and PK of Multiple Ascending Doses of GC021109 in Subjects With Mild to Moderate Alzheimer\u2019s Disease","author":"GliaCure, Inc","year":"2016"},{"key":"key20170509113253506_ref1-bib163","volume-title":"NCT02389413 Safety and Tolerability of PQ912 in Subjects With Early Alzheimer\u2019s Disease (SAPHIR)","author":"Probiodrug","year":"2016"},{"key":"key20170509113253506_ref1-bib164","volume-title":"NCT02406027 An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer\u2019s Disease Spectrum","author":"Janssen Research & Development, LLC","year":"2016"},{"key":"key20170509113253506_ref1-bib165","volume-title":"NCT02431468 A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer\u2019s Disease","author":"Neurotrope Bioscience, Inc","year":"2016"},{"key":"key20170509113253506_ref1-bib166","volume-title":"NCT02434718 Single and Multiple Ascending Dose Study of BIIB037 in Japanese Participants With Alzheimer\u2019s Disease (PROPEL)","author":"Biogen","year":"2016"},{"key":"key20170509113253506_ref1-bib167","volume-title":"NCT02477800 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer\u2019s Disease (ENGAGE)","author":"Biogen","year":"2016"},{"key":"key20170509113253506_ref1-bib168","volume-title":"NCT02484547 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer\u2019s Disease (EMERGE)","author":"Biogen","year":"2016"},{"key":"key20170509113253506_ref1-bib169","volume-title":"NCT02503501 Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer\u2019s Disease","author":"HealthPartners Institute","year":"2016"},{"key":"key20170509113253506_ref1-bib170","volume-title":"NCT02547818 Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer\u2019s Disease","author":"AZTherapies, Inc.","year":"2016"},{"key":"key20170509113253506_ref1-bib171","volume-title":"NCT02551809 Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer\u2019s Disease (AD) Patients","author":"United Neuroscience Ltd","year":"2016"},{"key":"key20170509113253506_ref1-bib172","volume-title":"NCT02579252 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer\u2019s Disease (ADAMANT)","author":"Axon Neuroscience SE","year":"2016"},{"key":"key20170509113253506_ref1-bib173","author":"Longeveron LLC","year":"2016","journal-title":"NCT02600130 Allogeneic Human Mesenchymal Stem Cell Infusion Versus Placebo in Patients With Alzheimer\u2019s Disease"},{"key":"key20170509113253506_ref1-bib174","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer\u2019s disease","volume":"141","author":"Rosen","year":"1984","journal-title":"Am J Psychiatry"},{"key":"key20170509113253506_ref1-bib175","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/gps.2319","article-title":"The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer\u2019s disease","volume":"25","author":"Rockwood","year":"2010","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib176","volume-title":"Dementia Outcomes Measurement Suite (DOMS) Project: Final Report","author":"Sansoni","year":"2007"},{"key":"key20170509113253506_ref1-bib177","first-page":"69","article-title":"Adaptation and normalization of the Alzheimer\u2019s disease Assessment Scale for Spain (NORMACODEM) (II)","volume":"12","author":"Pe\u00f1a-Casanova","year":"1997","journal-title":"Neurologia"},{"key":"key20170509113253506_ref1-bib178","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/jnnp-2011-300881","article-title":"What is the clinically relevant change on the ADAS-Cog?","volume":"83","author":"Schrag","year":"2011","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"key20170509113253506_ref1-bib179","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/ane.12153","article-title":"Psychometric evaluation of ADAS-Cog and NTB for measuring drug response","volume":"129","author":"Karin","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"key20170509113253506_ref1-bib180","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/1533317509350298","article-title":"Item analysis of ADAS-Cog: effect of baseline cognitive impairment in a clinical AD trial","volume":"25","author":"Sevigny","year":"2010","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"key20170509113253506_ref1-bib181","first-page":"1","article-title":"Examining the reliability of ADAS-Cog change scores","author":"Grochowalski","year":"2015","journal-title":"Aging Neuropsychol Cogn"},{"key":"key20170509113253506_ref1-bib182","first-page":"627","article-title":"Alzheimer\u2019s Disease Assessment Scale (ADAS)","volume":"24","author":"Mohs","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"key20170509113253506_ref1-bib183","first-page":"474","article-title":"The reliability and validity of the Alzheimer\u2019s Disease Assessment Scale Cognitive Subscale (ADAS-Cog) among the elderly Chinese in Hong Kong","volume":"29","author":"Chu","year":"2000","journal-title":"Ann Acad Med Singap"},{"key":"key20170509113253506_ref1-bib184","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000048629","article-title":"The Alzheimer\u2019s Disease Assessment Scale: findings from a low education population","volume":"13","author":"Liu","year":"2002","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib185","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1017\/S1041610297004298","article-title":"Alzheimer\u2019s Disease Assessment Scale: reliability and validity in a multicenter clinical trial","volume":"9","author":"Weyer","year":"1997","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib186","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/089198879400700202","article-title":"Factor structure and reliability of the Alzheimer\u2019s Disease Assessment Scale in a multicenter trial with linopirdine","volume":"7","author":"Kim","year":"1994","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"key20170509113253506_ref1-bib187","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u2018Mini-mental state\u2019. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"key20170509113253506_ref1-bib188","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1177\/153331750001500604","article-title":"Mini mental state examination (MMSE): a validation study in Greece","volume":"15","author":"Fountoulakis","year":"2000","journal-title":"Am J Alzheimers Dis Other Dement"},{"key":"key20170509113253506_ref1-bib189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1076\/anec.11.1.1.29366","article-title":"Validation of a modified version of the Mini-Mental State Examination (MMSE) in Spanish","volume":"11","author":"Beaman","year":"2004","journal-title":"Aging Neuropsychol Cogn"},{"key":"key20170509113253506_ref1-bib190","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1080\/09084282.2010.499773","article-title":"Validation of a Mini-Mental State Examination (MMSE) for the Persian population: a pilot study","volume":"17","author":"Ansari","year":"2010","journal-title":"Appl Neuropsychol"},{"key":"key20170509113253506_ref1-bib191","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/1874205X01509010053","article-title":"Validation Study of the Mini-Mental State Examination in Urdu Language for Pakistani Population","volume":"9","author":"Awan","year":"2015","journal-title":"Open Neurol J"},{"key":"key20170509113253506_ref1-bib192","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.nrl.2013.07.003","article-title":"Should the mini-mental state examination be retired?","volume":"29","author":"Carnero-Pardo","year":"2014","journal-title":"Neurologia"},{"key":"key20170509113253506_ref1-bib193","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1468-1331.2006.01185.x","article-title":"Mini-Mental State Examination: standardization and validation for the elderly Slovenian population","volume":"13","author":"Rakusa","year":"2006","journal-title":"Eur J Neurol"},{"key":"key20170509113253506_ref1-bib194","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1002\/gps.2607","article-title":"Determining the minimum clinically important differences for outcomes in the DOMINO trial","volume":"26","author":"Howard","year":"2011","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib195","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/(SICI)1097-0258(20000615\/30)19:11\/12<1421::AID-SIM434>3.0.CO;2-P","article-title":"Measuring cognitive change in a cohort of patients with Alzheimer\u2019s disease","volume":"19","author":"Galasko","year":"2000","journal-title":"Stat Med"},{"key":"key20170509113253506_ref1-bib196","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1212\/WNL.40.8.1225","article-title":"Longitudinal evaluation of dementia of the Alzheimer type: a comparison of 3 standardized mental status examinations","volume":"40","author":"Salmon","year":"1990","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib197","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1017\/S1041610214000416","article-title":"Review of brief cognitive tests for patients with suspected dementia","volume":"26","author":"Velayudhan","year":"2014","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib198","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/gps.585","article-title":"Psychometric properties of Clock Drawing Test and MMSE or Short Performance Test (SKT) in dementia screening in a memory clinic population","volume":"17","author":"Schramm","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib199","first-page":"158","article-title":"Validation of an Alzheimer\u2019s disease assessment battery in Asian participants with mild to moderate Alzheimer\u2019s disease","volume":"3","author":"Shen","year":"2014","journal-title":"Am J Neurodegener Dis"},{"key":"key20170509113253506_ref1-bib200","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.acn.2004.11.004","article-title":"Test\u2013retest reliable coefficients and 5-year change scores for the MMSE and 3MS","volume":"20","author":"Tombaugh","year":"2005","journal-title":"Arch Clin Neuropsychol"},{"key":"key20170509113253506_ref1-bib201","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/apnr.2000.9231","article-title":"An examination of psychometric properties of the mini-mental state examination and the standardized mini-mental state examination: implications for clinical practice","volume":"13","author":"Pangman","year":"2000","journal-title":"Appl Nurs Res"},{"key":"key20170509113253506_ref1-bib202","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1097\/WAD.0b013e3181b76415","article-title":"The CERAD Neuropsychologic Battery Total Score and the progression of Alzheimer disease","volume":"24","author":"Rossetti","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib203","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000380815","article-title":"The CERAD Neuropsychological Battery in patients with frontotemporal lobar degeneration","volume":"5","author":"Haanp\u00e4\u00e4","year":"2015","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"key20170509113253506_ref1-bib204","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/JGP.0b013e3181cab764","article-title":"Total scores of the CERAD neuropsychological assessment battery: validation for mild cognitive impairment and dementia patients with diverse etiologies","volume":"18","author":"Seo","year":"2010","journal-title":"Am J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib205","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ageing\/23.6.449","article-title":"Translation of clinical and neuropsychological instruments into French: the CERAD experience","volume":"23","author":"Demers","year":"1994","journal-title":"Age Ageing"},{"key":"key20170509113253506_ref1-bib206","first-page":"826","article-title":"The Russian Adaptation of the CERAD Battery (CERAD-RA)","volume":"16","author":"Glezerman","year":"2001","journal-title":"Arch Clin Neuropsychol"},{"key":"key20170509113253506_ref1-bib207","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1017\/S1041610211001153","article-title":"Effects of age, education and gender in the Consortium to Establish a Registry for the Alzheimer\u2019s Disease (CERAD)-Neuropsychological Assessment Battery for Cantonese-speaking Chinese elders","volume":"23","author":"Liu","year":"2011","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib208","doi-asserted-by":"crossref","first-page":"P47","DOI":"10.1093\/geronb\/57.1.P47","article-title":"Development of the Korean version of the Consortium to Establish a Registry for Alzheimer\u2019s Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment batteries","volume":"57","author":"Lee","year":"2002","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"key20170509113253506_ref1-bib209","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000356725","article-title":"CERAD neuropsychological total scores reflect cortical thinning in prodromal Alzheimer\u2019s disease","volume":"3","author":"Paajanen","year":"2013","journal-title":"Dement Geriatr Cogn Disord Extra"},{"key":"key20170509113253506_ref1-bib210","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1017\/S1041610213000653","article-title":"Progression of Alzheimer\u2019s disease during a three-year follow-up using the CERAD-NB total score: Kuopio ALSOVA study","volume":"25","author":"Hallikainen","year":"2013","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib211","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/geront\/41.3.406","article-title":"In-home assessment of dementia by nurses: experience using the CERAD evaluations. Consortium to Establish a Registry for Alzheimer\u2019s Disease","volume":"41","author":"Trapp-Moen","year":"2001","journal-title":"Gerontologist"},{"key":"key20170509113253506_ref1-bib212","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/arclin\/acp010","article-title":"Validity of the Cogstate brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex","volume":"24","author":"Maruff","year":"2009","journal-title":"Arch Clin Neuropsychol"},{"key":"key20170509113253506_ref1-bib213","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/0891988712447894","article-title":"Validity of a brief computerized cognitive screening test in dementia","volume":"25","author":"Hammers","year":"2012","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"key20170509113253506_ref1-bib214","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/1533317511411907","article-title":"Reliability of repeated cognitive assessment of dementia using a brief computerized battery","volume":"26","author":"Hammers","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"key20170509113253506_ref1-bib215","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000264823","article-title":"Evaluation of the usability of a brief computerized cognitive screening test in older people for epidemiological studies","volume":"34","author":"Fredrickson","year":"2010","journal-title":"Neuroepidemiology"},{"key":"key20170509113253506_ref1-bib216","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1080\/13803395.2011.643227","article-title":"Use of the Cogstate Brief Battery in the assessment of Alzheimer\u2019s disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study","volume":"34","author":"Lim","year":"2012","journal-title":"J Clin Exp Neuropsychol"},{"key":"key20170509113253506_ref1-bib217","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/2050-7283-1-30","article-title":"Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer\u2019s disease","volume":"1","author":"Maruff","year":"2013","journal-title":"BMC Psychol"},{"key":"key20170509113253506_ref1-bib218","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1001\/archneur.64.9.1323","article-title":"A neuropsychological test battery for use in Alzheimer disease clinical trials","volume":"64","author":"Harrison","year":"2007","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib219","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1080\/13854046.2013.875595","article-title":"Cognition in MCI and Alzheimer\u2019s disease: baseline data from a longitudinal study of the NTB","volume":"28","author":"Harrison","year":"2014","journal-title":"Clin Neuropsychol"},{"key":"key20170509113253506_ref1-bib220","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/1471-2377-10-87","article-title":"Behavioural symptoms in patients with Alzheimer\u2019s disease and their association with cognitive impairment","volume":"10","author":"Fern\u00e1ndez","year":"2010","journal-title":"BMC Neurol"},{"key":"key20170509113253506_ref1-bib221","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/jnnp.2009.204008","article-title":"The ADAS-cog in Alzheimer\u2019s disease clinical trials: psychometric evaluation of the sum and its parts","volume":"81","author":"Cano","year":"2010","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"key20170509113253506_ref1-bib222","first-page":"531","article-title":"Rates of change of common measures of impairment in senile dementia of the Alzheimer\u2019s type","volume":"24","author":"Yesavage","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"key20170509113253506_ref1-bib223","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1111\/j.1532-5415.1996.tb01838.x","article-title":"Improved reliability of the Standardized Alzheimer\u2019s Disease Assessment Scale (SADAS) compared with the Alzheimer\u2019s Disease Assessment Scale (ADAS)","volume":"44","author":"Standish","year":"1996","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib224","first-page":"9","article-title":"Behavioral symptoms in Alzheimer\u2019s disease: phenomenology and treatment","volume":"48","author":"Reisberg","year":"1987","journal-title":"J Clin Psychiatry"},{"key":"key20170509113253506_ref1-bib225","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0924-9338(00)00524-1","article-title":"Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer\u2019s Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability","volume":"16","author":"Monteiro","year":"2001","journal-title":"Eur Psychiatry"},{"key":"key20170509113253506_ref1-bib226","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/(SICI)1099-1166(199609)11:9%3C819::AID-GPS389%3E3.0.CO;2-S","article-title":"The Behavior Pathology in Alzheimer\u2019s Disease Rating Scale (BEHAVEAD): reliability and analysis of symptom category scores","volume":"11","author":"Sclan","year":"1996","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib227","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group","volume":"60","author":"Katz","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"key20170509113253506_ref1-bib228","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1017\/S1041610296002621","article-title":"The Empirical Behavioral Pathology in Alzheimer\u2019s Disease (E-BEHAVE-AD) Rating Scale","volume":"8","author":"Auer","year":"1996","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib229","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol Rep"},{"key":"key20170509113253506_ref1-bib230","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1176\/ajp.145.7.857","article-title":"Reliability of psychiatric scales in patients with dementia of the Alzheimer type","volume":"145","author":"Gottlieb","year":"1988","journal-title":"Am J Psychiatry"},{"key":"key20170509113253506_ref1-bib231","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1176\/ajp.152.9.1349","article-title":"The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer\u2019s Disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer\u2019s Disease","volume":"152","author":"Tariot","year":"1995","journal-title":"Am J Psychiatry"},{"key":"key20170509113253506_ref1-bib232","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jalz.2007.08.005","article-title":"Consortium to Establish a Registry for Alzheimer\u2019s Disease (CERAD): the first twenty years","volume":"4","author":"Fillenbaum","year":"2008","journal-title":"Alzheimers Dement"},{"key":"key20170509113253506_ref1-bib233","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/00002093-199700112-00006","article-title":"A longitudinal study of behavioral pathology across five levels of dementia severity in Alzheimer\u2019s disease: the CERAD Behavior Rating Scale for Dementia. The Alzheimer\u2019s Disease Cooperative Study","volume":"11","author":"Patterson","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib234","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1600-0447.1991.tb01429.x","article-title":"Validity and reliability of the Dysfunctional Behaviour Rating Instrument","volume":"84","author":"Molloy","year":"1991","journal-title":"Acta Psychiatr Scand"},{"key":"key20170509113253506_ref1-bib235","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1017\/S104161029700358X","article-title":"Dysfunctional Behavior Rating Instrument","volume":"8","author":"Molloy","year":"1996","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib236","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib237","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000017113","article-title":"Behavioral syndromes in Alzheimer\u2019s disease: description and correlates","volume":"10","author":"Frisoni","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib238","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1212\/WNL.46.1.130","article-title":"The spectrum of behavioral changes in Alzheimer\u2019s disease","volume":"46","author":"Mega","year":"1996","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib239","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jamda.2005.04.003","article-title":"The use of the occupational disruptiveness scale of the neuropsychiatric inventory-nursing home version to measure the impact of rivistagmine on the disruptive behaviour of nursing home residents with Alzheimer\u2019s disease","volume":"6","author":"Hatoum","year":"2005","journal-title":"J Am Med Dir Assoc"},{"key":"key20170509113253506_ref1-bib240","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1176\/jnp.10.1.55","article-title":"Differential neuropsychiatric symptom response in Tacrine in Alzhiemer\u2019s disease: relationship to symptom severity","volume":"10","author":"Kaufer","year":"1998","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"key20170509113253506_ref1-bib241","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000048636","article-title":"Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies","volume":"13","author":"Cummings","year":"2002","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib242","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1212\/WNL.48.5_Suppl_6.10S","article-title":"The Neuropsychiatric Inventory: assessing psychopathology in dementia patients","volume":"48","author":"Cummings","year":"1997","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib243","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1532-5415.1991.tb02897.x","article-title":"A new behavioral assessment scale for geriatric out- and in-patients: the NOSGER (Nurses\u2019 Observation Scale for Geriatric Patients)","volume":"39","author":"Spiegel","year":"1991","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib244","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1017\/S1041610296002864","article-title":"Validation of the NOSGER (Nurses\u2019 Observation Scale for Geriatric Patients): reliability and validity of a caregiver rating instrument","volume":"8","author":"Wahle","year":"1996","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib245","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/gps.930080406","article-title":"Clinical experience with the NOSGER (Nurses\u2019 Observation Scale for Geriatric Patients): tentative normative data and sensitivity to change","volume":"8","author":"Tremmel","year":"1993","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib246","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1532-5415.1970.tb01335.x","article-title":"Reliability and validity of a scale for assessing the functioning of geriatric patients","volume":"18","author":"Plutchik","year":"1970","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib247","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1037\/0882-7974.7.4.622","article-title":"Assessment of behavioral problems in dementia: the revised memory and behavior problems checklist","volume":"7","author":"Teri","year":"1992","journal-title":"Psychol Aging"},{"key":"key20170509113253506_ref1-bib248","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S1041610299005736","article-title":"Revised memory and behavior problems checklist in Taiwanese patients with Alzheimer\u2019s disease","volume":"11","author":"Fuh","year":"1999","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib249","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1017\/S1041610214002476","article-title":"Confirmatory factor analysis of the Spanish version of the revised memory and behavior problems checklist","volume":"27","author":"Nogales-Gonz\u00e1lez","year":"2015","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib250","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1300\/J018v22n03_09","article-title":"Revised memory and behavior problems checklist","volume":"22","author":"Johnson","year":"2001","journal-title":"Clin Gerontol"},{"key":"key20170509113253506_ref1-bib251","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-3956(99)00042-4","article-title":"Quantifying behavioral disturbance in Alzheimer\u2019s disease patients","volume":"34","author":"Weiner","year":"2000","journal-title":"J Psychiatr Res"},{"issue":"10","key":"key20170509113253506_ref1-bib252","doi-asserted-by":"crossref","DOI":"10.3310\/hta9100","article-title":"Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology","volume":"9","author":"Smith","year":"2005","journal-title":"Health Technol Assess"},{"key":"key20170509113253506_ref1-bib253","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1017\/S1041610210000207","article-title":"Validation of the Spanish version of the DEMQOL system","volume":"22","author":"Lucas-Carrasco","year":"2010","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib254","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1024\/1662-9647\/a000029","article-title":"Self-rated quality of life in mild cognitive impairment and Alzheimer\u2019s disease: the problem of affective distortion","volume":"24","author":"Berwig","year":"2011","journal-title":"GeroPsych"},{"key":"key20170509113253506_ref1-bib255","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/gps.2126","article-title":"Helping carers to care \u2013 the 10\/66 dementia research group\u2019s randomized control trial of a caregiver intervention in Russia","volume":"24","author":"Gavrilova","year":"2009","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib256","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0254-6272(13)60011-4","article-title":"Influence of acupuncture on cognitive function and markers of oxidative DNA damage in patients with vascular dementia","volume":"32","author":"Shi","year":"2012","journal-title":"J Tradit Chin Med"},{"key":"key20170509113253506_ref1-bib257","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1192\/bjp.bp.113.137414","article-title":"Maintenance cognitive stimulation therapy for dementia: single-blind, multicentre, pragmatic randomised controlled trial","volume":"204","author":"Orrell","year":"2014","journal-title":"Br J Psychiatry"},{"key":"key20170509113253506_ref1-bib258","doi-asserted-by":"publisher","first-page":"e002072","DOI":"10.1136\/bmjopen-2012-002072","article-title":"The Sydney Multisite Intervention of LaughterBosses and ElderClowns (SMILE) study: cluster randomised trial of humour therapy in nursing homes","volume":"3","author":"Low","year":"2013","journal-title":"BMJ Open"},{"key":"key20170509113253506_ref1-bib259","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jagp.2012.10.002","article-title":"Magnitude and causes of bias among family caregivers rating Alzheimer disease patients","volume":"21","author":"Schulz","year":"2013","journal-title":"Am J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib260","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/geront\/gnq033","article-title":"Measuring the experience and perception of suffering","volume":"50","author":"Schulz","year":"2010","journal-title":"Gerontologist"},{"key":"key20170509113253506_ref1-bib261","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol-a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"key20170509113253506_ref1-bib262","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11136-015-1065-9","article-title":"How does the EQ-5D perform when measuring quality of life in dementia against two other dementia-specific outcome measures?","volume":"25","author":"Aguirre","year":"2016","journal-title":"Qual Life Res"},{"key":"key20170509113253506_ref1-bib263","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jval.2010.08.002","article-title":"EQ-5D as a quality of life measure in people with dementia and their carers: evidence and key issues","volume":"14","author":"Hounsome","year":"2011","journal-title":"Value Health"},{"key":"key20170509113253506_ref1-bib264","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S0895-4356(03)00175-6","article-title":"Use of the EQ-5D among patients suffering from dementia","volume":"56","author":"Ankri","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"key20170509113253506_ref1-bib265","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11136-005-4364-8","article-title":"Utility-based quality of life measures in Alzheimer\u2019s disease","volume":"15","author":"Naglie","year":"2006","journal-title":"Qual Life Res"},{"key":"key20170509113253506_ref1-bib266","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/00005650-200108000-00003","article-title":"EQ-5D in patients with dementia: an investigation of inter-rater agreement","volume":"39","author":"Coucill","year":"2001","journal-title":"Med Care"},{"key":"key20170509113253506_ref1-bib267","first-page":"21","article-title":"Quality of life in Alzheimer\u2019s disease: patient and caregiver reports","volume":"5","author":"Logsdon","year":"1999","journal-title":"J Ment Health Aging"},{"key":"key20170509113253506_ref1-bib268","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/00002093-200310000-00002","article-title":"Whose quality of life is it anyway? The validity and reliability of the Quality of Life-Alzheimer\u2019s Disease (QoL-AD) scale","volume":"17","author":"Thorgrimsen","year":"2003","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib269","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/13607863.2014.915923","article-title":"Quality of life in dementia: a systematically conducted narrative review of dementia-specific measurement scales","volume":"19","author":"Bowling","year":"2015","journal-title":"Aging Ment Health"},{"key":"key20170509113253506_ref1-bib270","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1097\/JGP.0b013e3182006a7f","article-title":"Predictors of family caregiver ratings of patient quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer\u2019s Disease Quality of Life Study","volume":"19","author":"Naglie","year":"2011","journal-title":"Am J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib271","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/13607860902774386","article-title":"Transcultural adaptation and psychometric validation of a French-language version of the QoL-AD","volume":"13","author":"Wolak","year":"2009","journal-title":"Aging Ment Health"},{"key":"key20170509113253506_ref1-bib272","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/13607860500431652","article-title":"Improved quality of life and cognitive stimulation therapy in dementia","volume":"10","author":"Woods","year":"2006","journal-title":"Aging Ment Health"},{"key":"key20170509113253506_ref1-bib273","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1002\/gps.1271","article-title":"Quality of life in dementia \u2013 a one-year follow-up study","volume":"20","author":"Selwood","year":"2005","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib274","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/geront\/45.6.802","article-title":"Training community consultants to help family members improve dementia care: a randomized controlled trial","volume":"45","author":"Teri","year":"2005","journal-title":"Gerontologist"},{"key":"key20170509113253506_ref1-bib275","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/geront\/45.suppl_1.37","article-title":"Evaluating the quality of life of long-term care residents with dementia","volume":"45","author":"Sloane","year":"2005","journal-title":"Gerontologist"},{"key":"key20170509113253506_ref1-bib276","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1044\/1092-4388(2004\/085)","article-title":"Effects of cognitive-communication stimulation for Alzheimer\u2019s disease patients treated with donepezil","volume":"47","author":"Chapman","year":"2004","journal-title":"J Speech Lang Hear Res"},{"key":"key20170509113253506_ref1-bib277","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1002\/gps.1304","article-title":"A pilot study examining the effectiveness of maintenance Cognitive Stimulation Therapy (MCST) for people with dementia","volume":"20","author":"Orrell","year":"2005","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib278","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1192\/bjp.183.3.248","article-title":"Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial","volume":"183","author":"Spector","year":"2003","journal-title":"Br J Psychiatry"},{"key":"key20170509113253506_ref1-bib279","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1300\/J027v23n01_02","article-title":"Comparison of dementia-specific quality of life measures in adult day centers","volume":"23","author":"Edelman","year":"2004","journal-title":"Home Health Care Serv Q"},{"key":"key20170509113253506_ref1-bib280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/geront\/45.suppl_1.27","article-title":"A comparison of three methods of measuring dementia-specific quality of life: perspectives of residents, staff, and observers","volume":"45","author":"Edelman","year":"2005","journal-title":"Gerontologist"},{"key":"key20170509113253506_ref1-bib281","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/00006842-200205000-00016","article-title":"Assessing quality of life in older adults with cognitive impairment","volume":"64","author":"Logsdon","year":"2002","journal-title":"Psychosom Med"},{"key":"key20170509113253506_ref1-bib282","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/gps.1425","article-title":"Assessing quality of life in Taiwanese patients with Alzheimer\u2019s disease","volume":"21","author":"Fuh","year":"2006","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib283","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00002093-200607000-00007","article-title":"Quality of life (QoL) in dementia: a comparison of the perceptions of people with dementia and care staff in residential homes","volume":"20","author":"Spector","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib284","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1192\/bjp.bp.104.007658","article-title":"Quality of life of people with dementia in residential care homes","volume":"188","author":"Hoe","year":"2006","journal-title":"Br J Psychiatry"},{"key":"key20170509113253506_ref1-bib285","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/00019442-200506000-00005","article-title":"Neuropsychiatric symptoms and quality of life in Alzheimer disease","volume":"13","author":"Shin","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib286","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00002093-199700112-00005","article-title":"An inventory to assess activities of daily living for clinical trials in Alzheimer\u2019s disease. The Alzheimer\u2019s Disease Cooperative Study","volume":"11","author":"Galasko","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib287","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/01.wad.0000213873.25053.2b","article-title":"ADCS Prevention Instrument Project: assessment of instrumental activities of daily living for community-dwelling elderly individuals in dementia prevention clinical trials","volume":"20","author":"Galasko","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib288","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1185\/030079906X89685","article-title":"Effect of age on response to rivastigmine or donepezil in patients with Alzheimer\u2019s disease","volume":"22","author":"Bullock","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"key20170509113253506_ref1-bib289","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1111\/j.1532-5415.2004.52303.x","article-title":"Galantamine maintains ability to perform activities of daily living in patients with Alzheimer\u2019s disease","volume":"52","author":"Galasko","year":"2004","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib290","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000086613","article-title":"Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer\u2019s disease","volume":"20","author":"Brodaty","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib291","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/01.JGP.0000224350.82719.83","article-title":"Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial","volume":"14","author":"Peskind","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib292","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00002093-200108001-00003","article-title":"Assessing outcomes in Alzheimer disease","volume":"15","author":"Schneider","year":"2001","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib293","doi-asserted-by":"crossref","DOI":"10.1201\/b14307","volume-title":"Assessment Scales in Old Age Psychiatry","author":"Burns","year":"2004","edition":"2nd edn."},{"key":"key20170509113253506_ref1-bib294","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000350800","article-title":"Diagnostic validity of the Alzheimer\u2019s Disease Functional Assessment and Change Scale in mild cognitive impairment and mild to moderate Alzheimer\u2019s disease","volume":"37","author":"Manero","year":"2014","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib295","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/ageing\/25.2.113","article-title":"Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale","volume":"25","author":"Bucks","year":"1996","journal-title":"Age Ageing"},{"key":"key20170509113253506_ref1-bib296","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/1099-1166(200007)15:7<656::AID-GPS163>3.0.CO;2-Q","article-title":"The sensitivity to change over time of the Bristol Activities of Daily Living Scale in Alzheimer\u2019s disease","volume":"15","author":"Byrne","year":"2000","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib297","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1586\/14737175.2.5.669","article-title":"Bristol Activities of Daily Living Scale: a critical evaluation","volume":"2","author":"Bucks","year":"2002","journal-title":"Expert Rev Neurother"},{"key":"key20170509113253506_ref1-bib298","doi-asserted-by":"crossref","first-page":"M216","DOI":"10.1093\/geronj\/49.5.M216","article-title":"Assessing patient dependence in Alzheimer\u2019s disease","volume":"49","author":"Stern","year":"1994","journal-title":"J Gerontol"},{"key":"key20170509113253506_ref1-bib299","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/089198870001300402","article-title":"Review of outcome measurement instruments in Alzheimer\u2019s disease drug trials: psychometric properties of functional and quality of life scales","volume":"13","author":"Demers","year":"2000","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"key20170509113253506_ref1-bib300","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0167-4943(98)80005-8","article-title":"Functional evaluation of Alzheimer patients during clinical trials: a review","volume":"26","author":"Bavazzano","year":"1998","journal-title":"Arch Gerontol Geriatr"},{"key":"key20170509113253506_ref1-bib301","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5014\/ajot.53.5.471","article-title":"Development of a functional measure for persons with Alzheimer\u2019s disease: the disability assessment for dementia","volume":"53","author":"G\u00e9linas","year":"1999","journal-title":"Am J Occup Ther"},{"key":"key20170509113253506_ref1-bib302","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1159\/000086612","article-title":"Functional disabilities profile of Chinese elderly people with Alzheimer\u2019s disease \u2013 a validation study on the Chinese version of the disability assessment for dementia","volume":"20","author":"Mok","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib303","first-page":"278","article-title":"Development of the Korean Version of Disability Assessment for Dementia Scale (DAD-K) to assess function in dementia","volume":"7","author":"Suh","year":"2003","journal-title":"J Korean Geriatr Soc"},{"key":"key20170509113253506_ref1-bib304","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000113415","article-title":"Functional disability in early Alzheimer\u2019s disease \u2013 a validation study of the Italian version of the disability assessment for dementia scale","volume":"25","author":"De Vreese","year":"2008","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib305","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1590\/S0004-282X2007000500038","article-title":"Cross-cultural adaptation of the Disability Assessment for Dementia (DAD)","volume":"65","author":"Carthery-Goulart","year":"2007","journal-title":"Arq Neuropsiquiatr"},{"key":"key20170509113253506_ref1-bib306","doi-asserted-by":"publisher","first-page":"e1925","DOI":"10.1097\/MD.0000000000001925","article-title":"Validation study of the Spanish Version of the Disability Assessment for Dementia Scale","volume":"94","author":"S\u00e1nchez-P\u00e9rez","year":"2015","journal-title":"Medicine"},{"key":"key20170509113253506_ref1-bib307","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/0891988714532014","article-title":"Functional disability in Alzheimer disease: a validation study of the Turkish version of the Disability Assessment for Dementia Scale","volume":"27","author":"Tozlu","year":"2014","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"key20170509113253506_ref1-bib308","doi-asserted-by":"publisher","first-page":"e35619","DOI":"10.17795\/mejrh-35619","article-title":"Validity and reliability of the Persian version of the Disability Assessment for Dementia Scale","volume":"3","author":"Zangbar","year":"2016","journal-title":"Middle East J Rehabil Health"},{"key":"key20170509113253506_ref1-bib309","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00002093-200104000-00008","article-title":"The Disability Assessment for Dementia Scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease","volume":"15","author":"Feldman","year":"2001","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib310","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1017\/S1041610212002360","article-title":"Longitudinal changes in functional disability in Alzheimer\u2019s disease patients","volume":"25","author":"Arrighi","year":"2013","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib311","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000051229","article-title":"Galantamine: therapeutic effects beyond cognition","volume":"11","author":"Blesa","year":"2000","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib312","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000067974","article-title":"Galantamine provides sustained benefits in patients with \u2018advanced moderate\u2019 Alzheimer\u2019s disease for at least 12 months","volume":"15","author":"Blesa","year":"2003","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib313","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1159\/000017238","article-title":"Metrifonate therapy in Alzheimer\u2019s disease: a pooled analysis of four randomized, double-blind, placebo-controlled trials","volume":"11","author":"Farlow","year":"2000","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib314","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib315","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/089198870001300102","article-title":"Metrifonate enhances the ability of Alzheimer\u2019s disease patients to initiate, organize, and execute instrumental and basic activities of daily living","volume":"13","author":"G\u00e9linas","year":"2000","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"key20170509113253506_ref1-bib316","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1503\/cmaj.051432","article-title":"Attainment of treatment goals by people with Alzheimer\u2019s disease receiving galantamine: a randomized controlled trial","volume":"174","author":"Rockwood","year":"2006","journal-title":"CMAJ"},{"key":"key20170509113253506_ref1-bib317","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","article-title":"Measurement of functional activities in older adults in the community","volume":"37","author":"Pfeffer","year":"1982","journal-title":"J Gerontol"},{"key":"key20170509113253506_ref1-bib318","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1097\/WAD.0b013e3181e2fc84","article-title":"Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from very mild Alzheimer disease","volume":"24","author":"Teng","year":"2010","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib319","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1017\/S1041610297004845","article-title":"The interview for deterioration in daily living activities in dementia: agreement between primary and secondary caregivers","volume":"9","author":"Teunisse","year":"1997","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib320","first-page":"53","article-title":"Measurement of activities of daily living in patients with dementia living at home: development of a questionnaire","volume":"22","author":"Teunisse","year":"1991","journal-title":"Tijdschr Gerontol Geriatr"},{"key":"key20170509113253506_ref1-bib321","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1017\/S1041610298005377","article-title":"Clinical validity and utility of the interview for deterioration of daily living in dementia for Spanish-speaking communities NORMACODEM Group","volume":"10","author":"B\u00f6hm","year":"1998","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib322","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1017\/S1041610211001785","article-title":"Interview for Deterioration in Daily Living Activities in Dementia: construct and concurrent validity in patients with mild to moderate dementia","volume":"24","author":"Voigt-Radloff","year":"2012","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib323","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged. The index of Adl: a standardized measure of biological and psychosocial function","volume":"185","author":"Katz","year":"1963","journal-title":"JAMA"},{"key":"key20170509113253506_ref1-bib324","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2165\/00023210-200418130-00003","article-title":"Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment","volume":"18","author":"Desai","year":"2004","journal-title":"CNS Drugs"},{"key":"key20170509113253506_ref1-bib325","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/(SICI)1099-1166(200001)15:1%3C40::AID-GPS74%3E3.0.CO;2-S","article-title":"Clinical Lewy body dementia and the impact of vascular components","volume":"15","author":"Londos","year":"2000","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib326","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.2105\/AJPH.88.10.1452","article-title":"Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study","volume":"88","author":"Ag\u00fcero-Torres","year":"1998","journal-title":"Am J Public Health"},{"key":"key20170509113253506_ref1-bib327","first-page":"131","volume-title":"Handbook of Psychiatric Measures","author":"Katz","year":"2000"},{"key":"key20170509113253506_ref1-bib328","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/13607860020020627","article-title":"Interrater reliability of the physical self-maintenance scale and instrumental activities of daily living scale in a variety of health professional representatives","volume":"5","author":"Hokoishi","year":"2001","journal-title":"Aging Ment Health"},{"key":"key20170509113253506_ref1-bib329","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and instrumental activities of daily living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"key":"key20170509113253506_ref1-bib330","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/gerona\/61.7.726","article-title":"Physical and cognitive domains of the Instrumental Activities of Daily Living: validation in a multiethnic population of Asian older adults","volume":"61","author":"Ng","year":"2006","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"key20170509113253506_ref1-bib331","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1136\/jnnp.2008.155838","article-title":"A systematic review of Instrumental Activities of Daily Living scales in dementia: room for improvement","volume":"80","author":"Sikkes","year":"2009","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"key20170509113253506_ref1-bib332","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1046\/j.1365-2389.2003.51260.x","article-title":"Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer\u2019s disease and the effect on caregiver burden","volume":"51","author":"Feldman","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib333","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1532-5415.1993.tb06740.x","article-title":"Functional decline in Alzheimer\u2019s disease: a longitudinal study","volume":"41","author":"Green","year":"1993","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib334","volume-title":"N\u00fcrnberger-Alters-Inventar (NAI)-Testmanual und-Textband","author":"Oswald","year":"1995","edition":"3rd edn."},{"key":"key20170509113253506_ref1-bib335","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1080\/13607860220126790","article-title":"Family and professional caregivers\u2019 ratings of dementia symptoms and activities of daily living of day care patients: do differences change over time?","volume":"6","author":"Zank","year":"2002","journal-title":"Aging Ment Health"},{"key":"key20170509113253506_ref1-bib336","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/00002093-199700112-00004","article-title":"Validity and reliability of the Alzheimer\u2019s Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer\u2019s Disease Cooperative Study","volume":"11","author":"Schneider","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib337","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/01.wad.0000213878.47924.44","article-title":"ADCS Prevention Instrument Project: ADCS-clinicians\u2019 global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions","volume":"20","author":"Schneider","year":"2006","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib338","volume-title":"Clinical Global Impression Scale. ECDEU Assessment Manual for Psychopharmacology \u2013 Revised","author":"Guy","year":"1976"},{"key":"key20170509113253506_ref1-bib339","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1017\/S1041610296002645","article-title":"Clinical global impressions in Alzheimer\u2019s clinical trials","volume":"8","author":"Schneider","year":"1996","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib340","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000090296","article-title":"Reliability study on the Japanese version of the Clinician\u2019s Interview-Based Impression of Change","volume":"21","author":"Homma","year":"2006","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib341","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1212\/WNL.44.12.2315","article-title":"The Clinician Interview-Based Impression (CIBI): a clinician\u2019s global change rating scale in Alzheimer\u2019s disease","volume":"44","author":"Knopman","year":"1994","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib342","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000339953","article-title":"CIBIC Plus-J Assessment using a videotaped method in Alzheimer\u2019s disease patients","volume":"2","author":"Nakamura","year":"2012","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"key20170509113253506_ref1-bib343","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1192\/bjp.149.6.698","article-title":"CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia","volume":"149","author":"Roth","year":"1986","journal-title":"Br J Psychiatry"},{"key":"key20170509113253506_ref1-bib344","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1192\/bjp.114.512.797","article-title":"The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects","volume":"114","author":"Blessed","year":"1968","journal-title":"Br J Psychiatry"},{"key":"key20170509113253506_ref1-bib345","first-page":"1365","article-title":"Reliability and validity of the Korean version of Short Blessed Test (SBT-K) as a dementia screening instrument","volume":"38","author":"Lee","year":"1999","journal-title":"J Korean Neuropsychiatr Assoc"},{"key":"key20170509113253506_ref1-bib346","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1017\/S1041610297004183","article-title":"Screening for dementia: a preliminary study on the validity of the Chinese version of the Blessed-Roth Dementia Scale","volume":"9","author":"Lam","year":"1997","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib347","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1607-551X(09)70326-2","article-title":"Cut-off values of blessed dementia rating scale and its clinical application in elderly Taiwanese","volume":"22","author":"Yang","year":"2006","journal-title":"Kaohsiung J Med Sci"},{"key":"key20170509113253506_ref1-bib348","first-page":"7","article-title":"Use of behavioral scales in the diagnosis of dementia in the aged","volume":"91","author":"Vajdickov\u00e1","year":"1995","journal-title":"Ceska Slov Psychiatr"},{"key":"key20170509113253506_ref1-bib349","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1532-5415.1990.tb03473.x","article-title":"Brief screening tests versus clinical staging in senile dementia of the Alzheimer type","volume":"38","author":"Davis","year":"1990","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib350","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/geronj\/45.2.P69","article-title":"Comparison of two cognitive bedside screening instruments in nursing home residents: a factor analytic study","volume":"45","author":"Zillmer","year":"1990","journal-title":"J Gerontol"},{"key":"key20170509113253506_ref1-bib351","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/jnp.17.3.342","article-title":"Prevalence of apathy, dysphoria, and depression in relation to dementia severity in Alzheimer\u2019s disease","volume":"17","author":"Landes","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"key20170509113253506_ref1-bib352","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1600-0404.1992.tb05496.x","article-title":"Alzheimer\u2019s disease: correlational analysis of three screening tests and three behavioral scales","volume":"86","author":"Villardita","year":"1992","journal-title":"Acta Neurol Scand"},{"key":"key20170509113253506_ref1-bib353","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/089198879500800408","article-title":"Reliability of the Blessed Telephone Information-Memory-Concentration Test","volume":"8","author":"Kawas","year":"1995","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"key20170509113253506_ref1-bib354","first-page":"31","article-title":"Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease","volume":"10","author":"Clark","year":"1996","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib355","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/WAD.0b013e318194a324","article-title":"Rate of decline in Alzheimer disease measured by a Dementia Severity Rating Scale","volume":"23","author":"Xie","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib356","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/01.RLU.0000073662.73501.BD","article-title":"A metabolic imaging severity rating scale for the assessment of cognitive impairment","volume":"28","author":"Newberg","year":"2003","journal-title":"Clin Nucl Med"},{"key":"key20170509113253506_ref1-bib357","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1046\/j.1532-5415.2003.51456.x","article-title":"Why would caregivers not want to treat their relative\u2019s Alzheimer\u2019s disease?","volume":"51","author":"Karlawish","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib358","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0167-4943(82)90031-0","article-title":"A new rating scale for dementia syndromes","volume":"1","author":"Gottfries","year":"1982","journal-title":"Arch Gerontol Geriatr"},{"key":"key20170509113253506_ref1-bib359","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000051230","article-title":"The Gottfries\u2013Br\u00e5ne\u2013Steen scale: validity, reliability and application in anti-dementia drug trials","volume":"12","author":"Br\u00e5ne","year":"2001","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib360","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/alzrt48","article-title":"Review of Alzheimer\u2019s disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?","volume":"2","author":"Robert","year":"2010","journal-title":"Alzheimers Res Ther"},{"key":"key20170509113253506_ref1-bib361","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1532-5415.1974.tb01521.x","article-title":"A new scale for clinical assessment in geriatric populations: Sandoz Clinical Assessment \u2013 Geriatric (SCAG)","volume":"22","author":"Shader","year":"1974","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib362","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000213113","article-title":"The Sandoz Clinical Assessment-Geriatric (SCAG) scale. A general-purpose psychogeriatric rating scale","volume":"29","author":"Venn","year":"1983","journal-title":"Gerontology"},{"key":"key20170509113253506_ref1-bib363","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000106595","article-title":"A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia","volume":"8","author":"Herrmann","year":"1997","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib364","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1046\/j.1532-5415.2002.50209.x","article-title":"When home care ends \u2013 changes in the physical health of informal caregivers caring for dementia patients: a longitudinal study","volume":"50","author":"Gr\u00e4sel","year":"2002","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib365","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1192\/bjp.140.6.566","article-title":"A new clinical scale for the staging of dementia","volume":"140","author":"Hughes","year":"1982","journal-title":"Br J Psychiatry"},{"key":"key20170509113253506_ref1-bib366","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/archneurol.2010.115","article-title":"Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer\u2019s coordinating center database","volume":"67","author":"O\u2019Bryant","year":"2010","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib367","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1590\/S0034-89102005000600007","article-title":"Validity of the Portuguese version of Clinical Dementia Rating","volume":"39","author":"Monta\u00f1o","year":"2005","journal-title":"Rev Saude Publica"},{"key":"key20170509113253506_ref1-bib368","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/WAD.0b013e31811ff2b4","article-title":"Validity of the clinical dementia rating scale for the detection and staging of dementia in Brazilian patients","volume":"21","author":"Chaves","year":"2007","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib369","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/ana.410310303","article-title":"Mild senile dementia of the Alzheimer type 4. Evaluation of intervention","volume":"31","author":"Berg","year":"1992","journal-title":"Ann Neurol"},{"key":"key20170509113253506_ref1-bib370","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1007\/BF01291795","article-title":"Velnacrine for the treatment of Alzheimer\u2019s disease: a double-blind, placebo-controlled trial. The Mentane Study Group","volume":"103","author":"Zemlan","year":"1996","journal-title":"J Neural Transm"},{"key":"key20170509113253506_ref1-bib371","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJM199704243361704","article-title":"A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer\u2019s disease. The Alzheimer\u2019s Disease Cooperative Study","volume":"336","author":"Sano","year":"1997","journal-title":"N Engl J Med"},{"key":"key20170509113253506_ref1-bib372","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/gps.1038","article-title":"A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer\u2019s disease","volume":"19","author":"Jones","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib373","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/jnnp.2003.029074","article-title":"Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer\u2019s disease","volume":"75","author":"Rockwood","year":"2004","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"key20170509113253506_ref1-bib374","first-page":"86","article-title":"Recent data on the natural history of Alzheimer\u2019s disease: results from the REAL.FR Study","volume":"9","author":"Cortes","year":"2005","journal-title":"J Nutr Health Aging"},{"key":"key20170509113253506_ref1-bib375","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/089198879901200108","article-title":"Defining meaningful change in Alzheimer\u2019s disease trials: the donepezil experience","volume":"12","author":"McLendon","year":"1999","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"key20170509113253506_ref1-bib376","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/j.1532-5415.2001.49266.x","article-title":"A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer\u2019s disease in the nursing home setting","volume":"49","author":"Tariot","year":"2001","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib377","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000017208","article-title":"A 6-month, double-blind, placebo-controlled trial of eptastigmine in Alzheimer\u2019s disease","volume":"11","author":"Imbimbo","year":"2000","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib378","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1212\/WNL.50.1.136","article-title":"A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer\u2019s disease. Donepezil Study Group","volume":"50","author":"Rogers","year":"1998","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib379","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000017126","article-title":"The effects of donepezil in Alzheimer\u2019s disease \u2013 results from a multinational trial","volume":"10","author":"Burns","year":"1999","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib380","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000110773","article-title":"Comparison of seven psychometric instruments used for evaluation of treatment effect in Alzheimer\u2019s dementia","volume":"9","author":"Summers","year":"1990","journal-title":"Neuroepidemiology"},{"key":"key20170509113253506_ref1-bib381","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1159\/000088494","article-title":"Donepezil in vascular dementia: combined analysis of two large-scale clinical trials","volume":"20","author":"Rom\u00e1n","year":"2005","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib382","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4088\/PCC.v08n0501","article-title":"Adding memantine to rivastigmine therapy in patients with mild to moderate Alzheimer\u2019s disease: results of a 12-week, open-label pilot study","volume":"8","author":"Riepe","year":"2006","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"key20170509113253506_ref1-bib383","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00002093-200107000-00007","article-title":"Interobserver disagreements on clinical dementia rating assessment: interpretation and implications for training","volume":"15","author":"Tractenberg","year":"2001","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib384","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1176\/jnp.17.1.51","article-title":"Independence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer\u2019s disease: a factor analytic approach","volume":"17","author":"Tractenberg","year":"2005","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"key20170509113253506_ref1-bib385","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00002093-199903000-00005","article-title":"Informant-based staging of dementia using the clinical dementia rating","volume":"13","author":"Waite","year":"1999","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib386","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1532-5415.2000.tb05004.x","article-title":"Interrater reliability of the Clinical Dementia Rating in a multicenter trial","volume":"48","author":"Rockwood","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib387","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1212\/WNL.47.5.1194","article-title":"Cross-national interrater reliability of dementia diagnosis in the elderly and factors associated with disagreement","volume":"47","author":"O\u2019Connor","year":"1996","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib388","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/gps.385","article-title":"Reliability and validity of a chronic care facility adaptation of the Clinical Dementia Rating scale","volume":"16","author":"Marin","year":"2001","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib389","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/WNL.48.6.1508","article-title":"Clinical dementia rating training and reliability in multicenter studies: the Alzheimer\u2019s Disease Cooperative Study experience","volume":"48","author":"Morris","year":"1997","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib390","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/archneur.1989.00520470070029","article-title":"Reliability of clinical nurse specialists in the staging of dementia","volume":"46","author":"McCulla","year":"1989","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib391","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/archneur.55.9.1185","article-title":"Regional distribution of neuritic plaques in the nondemented elderly and subjects with very mild Alzheimer disease","volume":"55","author":"Haroutunian","year":"1998","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib392","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/archneur.1988.00520250037015","article-title":"Reliability of the Washington University Clinical Dementia Rating","volume":"45","author":"Burke","year":"1988","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib393","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1017\/S1041610207005261","article-title":"Global measures: utility in defining and measuring treatment response in dementia","volume":"19","author":"Reisberg","year":"2007","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib394","first-page":"612","article-title":"The validity of the Korean version of Global Deterioration Scale","volume":"20","author":"Choi","year":"2002","journal-title":"J Korean Neurol Assoc"},{"key":"key20170509113253506_ref1-bib395","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00002093-199907000-00006","article-title":"Correlational analysis of five commonly used measures of mental status\/functional abilities in patients with Alzheimer disease","volume":"13","author":"Solomon","year":"1999","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib396","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1177\/1533317514534761","article-title":"Correlational analysis of 5 commonly used measures of cognitive functioning and mental status: an update","volume":"29","author":"Solomon","year":"2014","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"key20170509113253506_ref1-bib397","first-page":"190","article-title":"An empirical evaluation of the Global Deterioration Scale for Staging Alzheimer\u2019s Disease","volume":"149","author":"Eisdorfer","year":"1992","journal-title":"Am J Psychiatry"},{"key":"key20170509113253506_ref1-bib398","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1017\/S1041610296002566","article-title":"Overview of methodologic issues for pharmacologic trials in mild, moderate, and severe Alzheimer\u2019s disease","volume":"8","author":"Reisberg","year":"1996","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib399","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1017\/S1041610296002608","article-title":"Reliability of the Modified Ordinal Scales of Psychological Development: a cognitive assessment battery for severe dementia","volume":"8","author":"Auer","year":"1996","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib400","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00002093-200304000-00008","article-title":"Interchanging scores between clinical dementia rating scale and global deterioration scale","volume":"17","author":"Choi","year":"2003","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib401","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0306-4522(99)00476-5","article-title":"The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer\u2019s disease","volume":"95","author":"Bobinski","year":"1999","journal-title":"Neuroscience"},{"key":"key20170509113253506_ref1-bib402","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1212\/WNL.58.5.750","article-title":"Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia","volume":"58","author":"Jack","year":"2002","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib403","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jalz.2015.01.001","article-title":"Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol","volume":"11","author":"Apostolova","year":"2015","journal-title":"Alzheimers Dement"},{"key":"key20170509113253506_ref1-bib404","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1212\/WNL.56.10.1386","article-title":"Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia","volume":"56","author":"O\u2019Brien","year":"2001","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib405","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1212\/01.WNL.0000110315.26026.EF","article-title":"Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD","volume":"62","author":"Jack","year":"2004","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib406","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1212\/WNL.52.8.1687","article-title":"Correlation between rates of brain atrophy and cognitive decline in AD","volume":"52","author":"Fox","year":"1999","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib407","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1212\/01.wnl.0000344568.09360.31","article-title":"Hippocampal atrophy rates in Alzheimer disease: added value over whole brain volume measures","volume":"72","author":"Henneman","year":"2009","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib408","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1212\/01.wnl.0000311446.61861.e3","article-title":"Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors","volume":"70","author":"Sluimer","year":"2008","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib409","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.neurobiolaging.2008.06.016","article-title":"Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study","volume":"31","author":"Sluimer","year":"2010","journal-title":"Neurobiol Aging"},{"key":"key20170509113253506_ref1-bib410","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1093\/brain\/awp062","article-title":"Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer\u2019s disease: implications for sequence of pathological events in Alzheimer\u2019s disease","volume":"132","author":"Jack","year":"2009","journal-title":"Brain"},{"key":"key20170509113253506_ref1-bib411","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ana.20889","article-title":"Amyloid load and cerebral atrophy in Alzheimer\u2019s disease: an 11C-PIB positron emission tomography study","volume":"60","author":"Archer","year":"2006","journal-title":"Ann Neurol"},{"key":"key20170509113253506_ref1-bib412","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1017\/S0317167100005734","article-title":"A comprehensive analysis of MRI research risks: in support of full disclosure","volume":"34","author":"Marshall","year":"2007","journal-title":"Can J Neurol Sci"},{"key":"key20170509113253506_ref1-bib413","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1148\/radiol.2323030830","article-title":"MR procedures: biologic effects, safety, and patient care","volume":"232","author":"Shellock","year":"2004","journal-title":"Radiology"},{"key":"key20170509113253506_ref1-bib414","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0005-7967(98)00110-7","article-title":"Evidence for fear of restriction and fear of suffocation as components of claustrophobia","volume":"37","author":"Harris","year":"1999","journal-title":"Behav Res Ther"},{"key":"key20170509113253506_ref1-bib415","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0005-7916(94)90005-1","article-title":"Anxiety and its determinants in patients undergoing magnetic resonance imaging","volume":"25","author":"Katz","year":"1994","journal-title":"J Behav Ther Exp Psychiatry"},{"key":"key20170509113253506_ref1-bib416","first-page":"77","volume-title":"Geriatric Psychiatry: A Handbook for Psychiatrics and Primary Care Physicians","author":"Mattis","year":"1976"},{"key":"key20170509113253506_ref1-bib417","first-page":"103","article-title":"Detection of dementia in the elderly using Telephone Screening of Cognitive Status","volume":"6","author":"Welsh","year":"1993","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"key20170509113253506_ref1-bib418","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1017\/S1041610203009220","article-title":"General measures of cognition","volume":"15","author":"Ferris","year":"2003","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib419","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/089198879100400406","article-title":"A new assessment tool for neuropsychopharmacologic research: the Computerized Neuropsychological Test Battery","volume":"4","author":"Veroff","year":"1991","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"key20170509113253506_ref1-bib420","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","article-title":"The FAB: a Frontal Assessment Battery at bedside","volume":"55","author":"Dubois","year":"2000","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib421","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1159\/000117297","article-title":"The Mental Deterioration Battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The Group for the Standardization of the Mental Deterioration Battery","volume":"36","author":"Carlesimo","year":"1996","journal-title":"Eur Neurol"},{"key":"key20170509113253506_ref1-bib422","doi-asserted-by":"crossref","DOI":"10.1037\/10020-000","volume-title":"The Measurement and Appraisal of Adult Intelligence","author":"Wechsler","year":"1939"},{"key":"key20170509113253506_ref1-bib423","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1037\/1040-3590.2.3.298","article-title":"Assessment of the severely impaired patient: description and validation of a new neuropsychological test battery","volume":"2","author":"Saxton","year":"1990","journal-title":"Psychol Assess"},{"key":"key20170509113253506_ref1-bib424","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/002383099200500407","article-title":"The SKT neuropsychological test battery","volume":"5","author":"Overall","year":"1992","journal-title":"J Geriatr Psychiatry Neurol"},{"key":"key20170509113253506_ref1-bib425","volume-title":"Wechsler Memory Scale","author":"Wechsler","year":"1945"},{"key":"key20170509113253506_ref1-bib426","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S031716710001951X","article-title":"The aphasia quotient: the taxonomic approach to measurement of aphasic disability","volume":"1","author":"Kertesz","year":"1974","journal-title":"Can J Neurol Sci"},{"key":"key20170509113253506_ref1-bib427","volume-title":"Neuropsychological Assessment","author":"Lezak","year":"2004"},{"key":"key20170509113253506_ref1-bib428","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0022-5371(73)80034-9","article-title":"Selective reminding for analysis of memory and learning","volume":"12","author":"Buschke","year":"1973","journal-title":"J Verb Learn Verb Beh"},{"key":"key20170509113253506_ref1-bib429","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1001\/archneurpsyc.1945.02300090051008","article-title":"A visual retention test for clinical use","volume":"54","author":"Benton","year":"1945","journal-title":"Arch Neurol Psychiatry"},{"key":"key20170509113253506_ref1-bib430","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/(SICI)1099-1166(199706)12:6<619::AID-GPS554>3.0.CO;2-H","article-title":"The clock drawing test for dementia of the Alzheimer\u2019s type: a comparison of three scoring methods in a memory disorders clinic","volume":"12","author":"Brodaty","year":"1997","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib431","volume-title":"Multilingual Aplasia Examination","author":"Benton","year":"1983","edition":"2nd edn."},{"key":"key20170509113253506_ref1-bib432","volume-title":"The Wechsler Intelligence Scale for Children","author":"Wechsler","year":"1949"},{"key":"key20170509113253506_ref1-bib433","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00002093-199700112-00003","article-title":"Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer\u2019s Disease Assessment Scale that broaden its scope. The Alzheimer\u2019s Disease Cooperative Study","volume":"11","author":"Mohs","year":"1997","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib434","volume-title":"The Clinical Examination in Psychology","author":"Rey","year":"1964"},{"key":"key20170509113253506_ref1-bib435","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1037\/h0054651","article-title":"Studies of interference in serial verbal reactions","volume":"18","author":"Stroop","year":"1935","journal-title":"J Exp Psychol"},{"key":"key20170509113253506_ref1-bib436","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/85.4.665","article-title":"The token test: a sensitive test to detect receptive disturbances in aphasics","volume":"85","author":"De Renzi","year":"1962","journal-title":"Brain"},{"key":"key20170509113253506_ref1-bib437","volume-title":"The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation","author":"Reitan","year":"1985"},{"key":"key20170509113253506_ref1-bib438","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1532-5415.1986.tb04303.x","article-title":"Agitated behaviors in the elderly. II. Preliminary results in the cognitively deteriorated","volume":"34","author":"Cohen-Mansfield","year":"1986","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib439","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"key20170509113253506_ref1-bib440","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0006-3223(88)90038-8","article-title":"Cornell scale for depression in dementia","volume":"23","author":"Alexopoulos","year":"1998","journal-title":"Biol Psychiatry"},{"key":"key20170509113253506_ref1-bib441","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0022-3956(82)90033-4","article-title":"Development and validation of a geriatric depression screening scale: a preliminary report","volume":"17","author":"Yesavage","year":"1982","journal-title":"J Psychiatr Res"},{"key":"key20170509113253506_ref1-bib442","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key20170509113253506_ref1-bib443","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"key20170509113253506_ref1-bib444","first-page":"915","article-title":"A scale for the objective evaluation of the state of subjective well-being as a method for longitudinal studies","volume":"20","author":"von Zerssen","year":"1970","journal-title":"Arzneimittelforschung"},{"key":"key20170509113253506_ref1-bib445","first-page":"109","article-title":"Consensus Report of the Working Group on: Molecular and Biochemical Markers of Alzheimer\u2019s Disease","volume":"2","author":"National Institute on Aging Working Group","year":"1998","journal-title":"Neurobiol Aging"},{"key":"key20170509113253506_ref1-bib446","doi-asserted-by":"publisher","first-page":"h369","DOI":"10.1136\/bmj.h369","article-title":"Assessment and management of behavioral and psychological symptoms of dementia","volume":"350","author":"Kales","year":"2015","journal-title":"BMJ"},{"key":"key20170509113253506_ref1-bib447","first-page":"976","article-title":"Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study","volume":"13","author":"Ryu","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib448","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/JGP.0b013e3181d6b68d","article-title":"Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease","volume":"18","author":"Spalletta","year":"2010","journal-title":"Am J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib449","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1176\/appi.ajp.162.11.1996","article-title":"Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia","volume":"162","author":"Livingston","year":"2005","journal-title":"Am J Psychiatry"},{"key":"key20170509113253506_ref1-bib450","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000357839","article-title":"The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review","volume":"38","author":"Reisberg","year":"2014","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib451","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/j.1532-5415.1986.tb04302.x","article-title":"Agitated behaviors in the elderly. I. A conceptual review","volume":"34","author":"Cohen-Mansfield","year":"1986","journal-title":"J Am Geriatr Soc"},{"key":"key20170509113253506_ref1-bib452","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","article-title":"Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease","volume":"366","author":"Howard","year":"2012","journal-title":"N Engl J Med"},{"key":"key20170509113253506_ref1-bib453","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/ejcn.2014.172","article-title":"Nutritional status and quality of life in different populations of older people in Poland","volume":"68","author":"Kostka","year":"2014","journal-title":"Eur J Clin Nutr"},{"key":"key20170509113253506_ref1-bib454","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1192\/bjp.180.2.161","article-title":"Rating scales in old age psychiatry","volume":"180","author":"Burns","year":"2002","journal-title":"Br J Psychiatry"},{"key":"key20170509113253506_ref1-bib455","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/13607863.2014.915920","article-title":"Activities of daily living and quality of life across different stages of dementia: a UK study","volume":"19","author":"Giebel","year":"2015","journal-title":"Aging Ment Health"},{"key":"key20170509113253506_ref1-bib456","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/BF00422219","article-title":"Developing and evaluating cross-cultural instruments from minimum requirements to optimal models","volume":"2","author":"Bullinger","year":"1993","journal-title":"Qual Life Res"},{"key":"key20170509113253506_ref1-bib457","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/geront\/33.2.205","article-title":"The perspective of the patient with Alzheimer\u2019s disease: a neglected dimension of dementia research","volume":"33","author":"Cotrell","year":"1993","journal-title":"Gerontologist"},{"key":"key20170509113253506_ref1-bib458","first-page":"7","article-title":"Conceptualisation of quality of life in dementia","volume":"5","author":"Brod","year":"1995","journal-title":"J Ment Health Aging"},{"key":"key20170509113253506_ref1-bib459","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1017\/S0144686X0000502X","article-title":"Towards a theory of dementia care: personhood and well-being","volume":"12","author":"Kitwood","year":"1992","journal-title":"Ageing Soc"},{"key":"key20170509113253506_ref1-bib460","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/geront\/39.1.25","article-title":"Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL)","volume":"39","author":"Brod","year":"1999","journal-title":"Gerontologist"},{"key":"key20170509113253506_ref1-bib461","volume-title":"Alzheimer\u2019s Disease Related Quality of Life (ADRQL) Users\u2019 Manual","author":"Black","year":"2002"},{"key":"key20170509113253506_ref1-bib462","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1017\/S0033291706009469","article-title":"The development of a new measure of health related quality of life for people with dementia: DEMQOL","volume":"37","author":"Smith","year":"2007","journal-title":"Psychol Med"},{"key":"key20170509113253506_ref1-bib463","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jalz.2007.04.384","article-title":"Commentary on \u2018Health economics and the value of therapy in Alzheimer\u2019s disease\u2019. Quality of life in dementia: development and use of a disease-specific measure of health-related quality of life in dementia","volume":"3","author":"Banerjee","year":"2007","journal-title":"Alzheimers Dement"},{"key":"key20170509113253506_ref1-bib464","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/gps.2090","article-title":"What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia","volume":"24","author":"Banerjee","year":"2009","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib465","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1136\/jnnp.2005.072983","article-title":"Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia","volume":"77","author":"Banerjee","year":"2006","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"key20170509113253506_ref1-bib466","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.jval.2011.10.016","article-title":"Estimating preference-based single index measures for dementia using DEMQOL and DEMQOL-Proxy","volume":"15","author":"Rowen","year":"2012","journal-title":"Value Health"},{"key":"key20170509113253506_ref1-bib467","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jval.2011.09.006","article-title":"Improving the measurement of QALYs in dementia: developing patient- and carer-reported health state classification systems using Rasch analysis","volume":"15","author":"Mulhern","year":"2012","journal-title":"Value Health"},{"issue":"5","key":"key20170509113253506_ref1-bib468","doi-asserted-by":"publisher","DOI":"10.3310\/hta17050","article-title":"Development of DEMQOL-U and DEMQOL-PROXY-U: generation of preference-based indices from DEMQOL and DEMQOL-PROXY for use in economic evaluation","volume":"17","author":"Mulhern","year":"2013","journal-title":"Health Technol Assess"},{"key":"key20170509113253506_ref1-bib469","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/1533317511418954","article-title":"Validity, reliability, and feasibility of clinical staging scales in dementia: a systematic review","volume":"26","author":"Rikkert","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"key20170509113253506_ref1-bib470","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3233\/JAD-2009-1124","article-title":"Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer\u2019s disease","volume":"18","author":"Zhou","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"key20170509113253506_ref1-bib471","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1159\/000351671","article-title":"Validation of the Addenbrooke\u2019s Cognitive Examination III in frontotemporal dementia and Alzheimer\u2019s disease","volume":"36","author":"Hsieh","year":"2013","journal-title":"Dement Geriatr Cogn Disord"},{"key":"key20170509113253506_ref1-bib472","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jalz.2016.01.002","article-title":"Longitudinal decline in mild to moderate Alzheimer\u2019s disease: analyses of placebo data from clinical trials","volume":"12","author":"Thomas","year":"2016","journal-title":"Alzheimers Dement"},{"key":"key20170509113253506_ref1-bib473","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1212\/01.wnl.0000240129.46080.53","article-title":"Relationship of vascular risk to the progression of Alzheimer disease","volume":"67","author":"Regan","year":"2006","journal-title":"Neurology"},{"key":"key20170509113253506_ref1-bib474","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/archneur.57.3.339","article-title":"Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects","volume":"57","author":"Fox","year":"2000","journal-title":"Arch Neurol"},{"key":"key20170509113253506_ref1-bib475","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.neuroimage.2009.12.059","article-title":"Robust atrophy rate measurement in Alzheimer\u2019s disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection","volume":"50","author":"Leung","year":"2010","journal-title":"Neuroimage"},{"key":"key20170509113253506_ref1-bib476","first-page":"88","article-title":"Development of an instrument to assess social functioning in dementia: the Social Functioning in Dementia scale (SF-DEM)","volume":"7","author":"Sommerlad","year":"2017","journal-title":"Alzheimers Dement"},{"key":"key20170509113253506_ref1-bib477","doi-asserted-by":"publisher","first-page":"c4184","DOI":"10.1136\/bmj.c4184","article-title":"Making decisions for people with dementia who lack capacity: qualitative study of family carers in UK","volume":"341","author":"Livingston","year":"2010","journal-title":"BMJ"},{"key":"key20170509113253506_ref1-bib478","doi-asserted-by":"crossref","DOI":"10.1002\/gps.4664","article-title":"Awareness of functional ability in people with early-stage dementia [published online ahead of print January 10 2017]","author":"Martyr","year":"2017","journal-title":"Int J Geriatr Psychiatry"},{"key":"key20170509113253506_ref1-bib479","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1111\/jocn.12519","article-title":"Managing medications: the role of informal caregivers of older adults and people living with dementia. A review of the literature","volume":"23","author":"Gillespie","year":"2014","journal-title":"J Clin Nurs"},{"key":"key20170509113253506_ref1-bib480","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1186\/1756-0500-7-463","article-title":"Perspectives of carers on medication management in dementia: lessons from collaboratively developing a research proposal","volume":"7","author":"Poland","year":"2014","journal-title":"BMC Res Notes"},{"key":"key20170509113253506_ref1-bib481","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1017\/S1041610214001203","article-title":"Researchers\u2019 perspectives on the role of study partners in dementia research","volume":"26","author":"Black","year":"2014","journal-title":"Int Psychogeriatr"},{"key":"key20170509113253506_ref1-bib482","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/WAD.0000000000000078","article-title":"Frequency and impact of informant replacement in Alzheimer disease research","volume":"29","author":"Grill","year":"2015","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"key20170509113253506_ref1-bib483","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/1471301207075625","article-title":"Participatory research: a method for process consent with persons who have dementia","volume":"6","author":"Dewing","year":"2007","journal-title":"Dementia"},{"key":"key20170509113253506_ref1-bib484","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2307\/3562038","article-title":"False hopes and best data: consent to research and the therapeutic misconception","volume":"17","author":"Appelbaum","year":"1987","journal-title":"Hastings Cent Rep"},{"key":"key20170509113253506_ref1-bib485","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0277-9536(97)00063-4","article-title":"Making sense of randomization; responses of parents of critically ill babies to random allocation of treatment in a clinical trial","volume":"45","author":"Snowdon","year":"1997","journal-title":"Soc Sci Med"},{"key":"key20170509113253506_ref1-bib486","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0277-9536(01)00197-6","article-title":"\u2018Why don\u2019t they just tell me straight, why allocate it?\u2019 The struggle to make sense of participating in a randomised controlled trial","volume":"55","author":"Featherstone","year":"2002","journal-title":"Soc Sci Med"},{"key":"key20170509113253506_ref1-bib487","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/bmj.312.7024.185c","article-title":"How to get patients\u2019 consent to enter clinical trials. Reports of trials should state proportion of people who refuse to participate","volume":"312","author":"Riordan","year":"1996","journal-title":"BMJ"},{"key":"key20170509113253506_ref1-bib488","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0277-9536(94)E0092-7","article-title":"Who says yes? Identifying selection biases in a psychosocial intervention study of multiple sclerosis","volume":"40","author":"Schwartz","year":"1995","journal-title":"Soc Sci Med"},{"key":"key20170509113253506_ref1-bib489","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2125.1993.tb05687.x","article-title":"Patients\u2019 attitudes to participation in clinical trials","volume":"35","author":"Bevan","year":"1993","journal-title":"Br J Clin Pharmacol"},{"key":"key20170509113253506_ref1-bib490","first-page":"71","article-title":"Doing nothing is no choice: lay constructions of treatment decision-making among women with early-stage breast cancer","volume":"20","author":"Charles","year":"1978","journal-title":"Soc Sci Med"},{"key":"key20170509113253506_ref1-bib491","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1200\/jco.1995.13.5.1062","article-title":"Perceptions of cancer patients and their physicians involved in phase I trials","volume":"13","author":"Daugherty","year":"1995","journal-title":"J Clin Oncol"},{"key":"key20170509113253506_ref1-bib492","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/ecc.12184","article-title":"Hope for a cure and altruism are the main motives behind participation in phase 3 clinical cancer trials","volume":"24","author":"Godskesen","year":"2015","journal-title":"Eur J Cancer Care"},{"key":"key20170509113253506_ref1-bib493","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/00002820-199606000-00004","article-title":"Psychosocial aspects of participation in early anticancer drug trials. Report of a pilot study","volume":"19","author":"Cox","year":"1996","journal-title":"Cancer Nurs"},{"key":"key20170509113253506_ref1-bib494","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1517\/14728214.2016.1146678","article-title":"Emerging amyloid disease modifying drugs for Alzheimer\u2019s disease","volume":"21","author":"Galimberti","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"key":"key20170509113253506_ref1-bib495","volume-title":"Enhancing Translational Research and Clinical Development for Alzheimer\u2019s Disease and other Dementias","author":"Organisation for Economic Co-operation and Development","year":"2015"},{"key":"key20170509113253506_ref1-bib496","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jalz.2015.08.003","article-title":"Performance and complications of lumbar puncture in memory clinics: results of the multicenter lumbar puncture feasibility study","volume":"12","author":"Duits","year":"2016","journal-title":"Alzheimers Dement"},{"key":"key20170509113253506_ref1-bib497","volume-title":"Guidance for Industry Alzheimer\u2019s Disease: Developing Drugs for the Treatment of Early Stage Disease","author":"Food and Drug Administration","year":"2013"},{"key":"key20170509113253506_ref1-bib498","volume-title":"Draft Guideline on the Clinical Investigation of Medicines for the Treatment of Alzheimer\u2019s Disease and Other Dementias","author":"European Medicines Agency","year":"2016"},{"key":"key20170509113253506_ref1-bib499","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1474-4422(06)70677-9","article-title":"Disease-modifying trials in Alzheimer\u2019s disease: a European task force consensus","volume":"6","author":"Vellas","year":"2007","journal-title":"Lancet Neurol"},{"key":"key20170509113253506_ref1-bib500","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1474-4422(08)70087-5","article-title":"Endpoints for trials in Alzheimer\u2019s disease: a European task force consensus","volume":"7","author":"Vellas","year":"2008","journal-title":"Lancet Neurol"},{"key":"key20170509113253506_ref1-bib501","volume-title":"Standard Set for Dementia","author":"ICHOM","year":"2016"},{"key":"key20170509113253506_ref1-bib502","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/13607860801919850","article-title":"A European consensus on outcome measures for psychosocial intervention research in dementia care","volume":"12","author":"Moniz-Cook","year":"2008","journal-title":"Aging Ment Health"},{"key":"key20170509113253506_ref1-bib503","volume-title":"Dementia Outcome Measures: Charting New Territory","author":"Mountain","year":"2015"},{"key":"key20170509113253506_ref1-bib504","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/j.1467-9566.2007.01027.x","article-title":"\u2018Ordinary people only\u2019: knowledge, representativeness, and the publics of public participation in healthcare","volume":"30","author":"Martin","year":"2008","journal-title":"Sociol Health Illn"},{"key":"key20170509113253506_ref1-bib505","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12916-016-0582-x","article-title":"Measures to assess commonly experienced symptoms for people with dementia in long-term care settings: a systematic review","volume":"14","author":"Ellis-Smith","year":"2016","journal-title":"BMC Med"},{"key":"key20170509113253506_ref1-bib506","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jalz.2016.01.004","article-title":"Impact of interventions to reduce Alzheimer\u2019s disease pathology on the prevalence of dementia in the oldest-old","volume":"12","author":"Brookmeyer","year":"2016","journal-title":"Alzheimers Dement"},{"key":"key20170509113253506_ref1-bib507","doi-asserted-by":"crossref","first-page":"S794","DOI":"10.1016\/j.jalz.2011.05.2276","article-title":"Cessation versus continuation of 12 months galantamine therapy in patients with Alzheimer\u2019s disease: a randomised, double blind, placebo controlled withdrawal trial","volume":"1","author":"Adami","year":"2011","journal-title":"Alzheimers Dement"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta21260\/hta21260.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002708","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta21260\/hta21260.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2010498","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T19:09:33Z","timestamp":1750360173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta21260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":507,"journal-issue":{"issue":"26","published-online":{"date-parts":[[2017,5]]}},"alternative-id":["10.3310\/hta21260"],"URL":"https:\/\/doi.org\/10.3310\/hta21260","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}